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ABSTRACT 
Diabetes Mellitus (DM) has become one of the most important metabolic 
diseases that reduces one’s quality of life and doubles the risk of early death. 
Amongst the major complications linked to DM, diabetic retinopathy (DR) leads 
to gradual loss of vision and blindness. DR is now the second cause of certifiable 
blindness among the working age adults in the UK. The lifetime costs to the UK 
government are calculated to be up to £327,000 per person, with almost 50% of 
these costs being attributed to loss of productivity caused by visual impairment 
and blindness. The UK is one of the leading countries in the implementation of 
DR screening programmes. The latter rely heavily on fundus imaging and grading 
using trained experts and subsequent referral to hospital for further clinical 
examination and evaluation depending on the grade of retinopathy. It is now 
known that subtle, structural changes in the retina that are linked to diabetes 
can precede detectable vascular changes. The former can affect one’s colour 
vision and this offers the potential of using changes in chromatic sensitivity as 
an early biomarker of retinal disease.   
The first part of this thesis focuses on measuring chromatic sensitivity using the 
colour assessment and diagnosis (CAD) test in diabetic subjects with varying 
degrees of retinopathy. The severity of colour vision loss is graded in comparison 
to other factors that are normally linked to diabetes, such as the type, grade, 
control methods and duration. The results of this study reveal losses of both red 
/ green and yellow / blue chromatic sensitivity in patients with diabetes, but the 
correlation with factors, normally associated with high risk of diabetes is low. 
The results from this study do, however, show that the magnitude of chromatic 
sensitivity losses correlates with the severity of diabetic retinopathy. 
The second, related study examines the effectiveness of intravitreal injection of 
a dexamethasone implant (Ozurdex) in patients with diabetic macular oedema 
(DMO) in stabilising and reducing loss of visual function and in particular the 
reduction in chromatic sensitivity up to 24 weeks. This treatment demonstrated 
efficacy in the treatment of chronic DMO and DMO which is resistant to anti-
VEGF treatment. The results show that intravitreal treatment with Ozurdex 
causes improvement is visual acuity, central retinal thickness and significant 
improvement in red / green chromatic sensitivity. 
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1 THE VISUAL SYSTEM 
1.1 ANATOMY OF THE EYE 
The eye is located within the orbital cavity surrounded by muscles, nerves, 
vessels and fatty tissue. It is made up of segments of two spheres of different 
sizes, the anterior, smaller segment is transparent and forms one-sixth of the 
eyeball while the posterior, larger segment is opaque and forms about five-
sixths of the eyeball. 
The eyeball consists of three layers (Figure1-1): 
1. The fibrous layer, composed of the sclera and cornea 
2. The vascular pigmented layer, composed of the uvea (iris, ciliary body and 
choroid) 
3. The nervous layer, i.e. the retina 
 
Figure 1-1: Anatomy of the human eye (http://zeiss-campus.magnet.fsu.edu) 
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1.1.1 The fibrous layer 
The sclera forms the posterior five-sixths of the eyeball and is opaque; it is about 
1mm thick posteriorly, thinning at the equator to 0.6mm (Snell and Lemp, 2001). 
The sclera may be divided into three layers, the episclera, the scleral stroma and 
the lamina fusca. The main function of the sclera is to provide a tough external 
framework that protects the intraocular contents from trauma and together 
with the intraocular pressure it helps preserve the shape of the eyeball. The 
sclera joins the cornea at the corneoscleral junction.  
The cornea is transparent; it forms the anterior one-sixth of the eyeball. The 
average corneal diameter is 10.6 mm vertically and about 11.7 mm horizontally. 
It is the main structure responsible for the refraction of light entering the eye. 
The average corneal thickness is 530 microns (Doughty and Zaman, 2000). It 
consists of 5 layers: the epithelium, Bowman’s layer (membrane), the stroma, 
Descemet’s membrane and the endothelium. The transparency of the cornea 
results from its avascularity and the uniform spacing of the collagen fibrils in the 
stroma. It transmits most of the visible and infrared light (IR) (300-2500 nm) with 
the maximum transmittance between 500-1300 nm. 
 
1.1.2 The vascular pigmented layer 
The uvea is the middle vascular layer of the eyeball. It consists of the iris, the 
ciliary body and the choroid. The iris is a thin pigmented diaphragm with a 
central aperture called the pupil. The pupil varies in diameter from 1 to 8 mm.  
The iris divides the space between the lens and the cornea into an anterior and 
 15 
 
a posterior chamber. The colour of the iris varies from light blue to dark brown 
depending on the amount of pigment in the melanocytes. The iris controls the 
amount of light entering through the pupil through its contractile ability to dilate 
and constrict the pupil. During accommodation for near vision, the pupil 
constricts to restrict the incoming light to the central part of the lens thus 
diminishing the spherical aberration. The periphery of the iris is attached to the 
anterior surface of the ciliary body.  
The ciliary body is a triangular structure; it is made up of the ciliary epithelium, 
the ciliary stroma and the ciliary muscle. The anterior surface of the ciliary body 
gives rise to the ciliary processes that produces the aqueous humour. The 
zonular fibres of the lens pass from the lens equator to attach to the anterior 
surface of the ciliary body in the intervals between the ciliary processes. 
Contraction of the ciliary muscle moves the apex of the ciliary processes towards 
the lens equator and relaxes the lens zonules, thus allowing accommodation 
(Figure 1-2). 
The choroid lies posterior to the ciliary body. It extends from the optic nerve 
posteriorly to the ciliary body anteriorly. It is extremely vascular and divided into 
three layers: the vessel layer, the capillary layer and Bruch’s membrane. The 
main function of the choroid is to provide the outer retina and the retinal 
pigment epithelium (RPE) with oxygen and nutrients through its 
choriocapillaries. 
The crystalline lens is a transparent biconvex structure situated behind the iris 
and pupil in front of the vitreous body. The lens is enveloped within an elastic 
capsule formed of type IV collagen fibrils embedded in a matrix of glycoproteins 
and sulphated glycosaminoglycan and suspended by zonules. The transparency 
of the lens is attributed to its avascularity, permeability of its capsule and its 
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pump mechanism. It accounts for 30% of the eye’s refractive power. It transmits 
light from the ultra-violet (UV) (300 nm) part of the spectrum to the 1900 nm 
range in the IR part. 
 
 
Figure 1-2: Sectional anatomy of the eye (Blausen gallery, 2014). 
 
1.1.3 The nervous layer – The retina 
The retina is the internal layer of the eyeball. It is where the neural processing 
of the optical image is initiated. It is continuous with the optic nerve posteriorly 
and it extends anteriorly to become the epithelium of the ciliary body and the 
iris. It consists of an outer pigmented segment and an inner neurosensory 
segment, these two segments are formed of 10 layers (Figure 1-3). 
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Figure 1-3: The different layers of human retina (adapted from Gray’s 
anatomy, 1918)  
 
The RPE is the outermost layer of the retina, and has several functions including 
the phagocytosis of the outer segments of the photoreceptors, the participation 
in the formation of rhodopsin and its dark pigmentation absorbs the light thus 
reducing the amount of light scatter in the eye. 
 
The main structures in the retina are the optic disc, the macula lutea and the 
peripheral retina (ora serrata). The optic disc is the point at which the optic 
nerve fibres carrying the visual signals exit the eye by piercing the sclera.  
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The macula lutea is an oval yellowish area at the centre of the retina. This 
yellowish colour is attributed to the yellow xanthophyll carotenoids, zeaxanthin 
and lutein. It measures about 5 mm in diameter and its centre lies about 5.5 mm 
temporal to the optic disc. The central depressed area in the centre of the 
macula is called the fovea; it is about 1.5 mm in diameter. The foveola is the 
central part of the fovea and has a diameter of 0.35 mm. The sharpest vision 
occurs at the macula because of its avascularity and dense cone mosaic.  
The neurosensory segment of the retina is formed of three main groups of 
neurons: the photoreceptors, the bipolar cells and the ganglion cells.  
 
1.2 PHOTORECEPTORS 
There are two types of photoreceptors, the rods and the cones. The rods are 
mainly responsible for vision in dim light (scotopic conditions), while the cones 
are adapted to bright lights (photobic conditions) and can resolve fine details 
and colour vision (CV). There is three different types of cones named short-, 
middle- or long-wavelength, or S, M and L cones. This classification is based on 
the sensitivity of the photopigments to short, middle or long wavelength light. 
There are about 110 to 125 million rods in the retina and about 6.3 to 6.8 million 
cones. The rods are absent at the foveola rising rapidly in number towards the 
periphery with the opposite happening with the cones which are most dense at 
the fovea and then decrease in number towards the periphery.  
Rods and cones have four distinct structural regions: outer segment (OS), inner 
segment (IS), cell body and synaptic terminal (Figure 1-4). The OS is filled with 
about 600 to 1000 membrane discs that contain the photochemical rhodopsin 
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molecules in the rods and photopsin molecules in the cones. The OS is 
connected to the IS by a connecting stalk that contains modified cilium. The IS 
in both rods and cones consists of two areas, the ellipsoid, which is situated next 
to the connecting stalk and the myoid located toward the vitreous, they contain 
numerous mitochondria, ribosomes and Golgi apparatus that provide the 
necessary energy for photo-transduction. The cell body of the photoreceptors is 
connected through microtubules to pear-shaped spherule in rods and expanded 
end in cones - called cone pedicles that contain many presynaptic vesicles and 
synapse with the dendrites of the bipolar cells. 
 
Figure 1-4: The main structure of rods and cones; the photopigment is located 
in the outer segment (OS). The OS is connected to the IS by a connecting stalk 
that contains modified cilium. At the base of the cell the spherule contain the 
presynaptic vesicles that synapse with the dendrites of the bipolar cells 
(created by Ivo Kruusamägi, 
https://upload.wikimedia.org/wikipedia/commons/4/48/Cone_cell_eng.png
). 
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When light falls on the retina, photon absorption by visual pigment rhodopsin 
triggers isomerization of 11 cis retinal to all trans retinal resulting in activation 
of rhodopsin that starts chain of actions with closure of the ion channels and 
inducing change in the electric potential of the photoreceptor. This will continue 
until trans is transformed back to cis. Similar biochemical events occur in cones. 
The signals generated are transmitted through the synapses. 
 
1.3 INTRA-RETINAL PATHWAYS 
Two main patterns exist for transmitting signals from photoreceptors, the 
vertical pathway and the lateral pathway. In the vertical pathway, rods and 
cones synapse with bipolar and ganglion cells. First post receptoral synapses 
takes place between the photoreceptors and the bipolar cell, which in turn 
synapses with a ganglion cell. The first synapse at the outer plexiform layer (OPL) 
is responsible for processing static information. The second synapse at inner 
plexiform layer (IPL) is responsible for processing phasic information. Signals 
from 120 rods converge to one ganglion cell while signals from 6 cones converge 
to one ganglion cell, this becomes one-one ratio at the fovea.  The lateral 
pathway for transmitting the signal involves the horizontal cells and amacrine 
cells which allows signals from neighbouring photoreceptors to transmit the 
signals through other bipolar or ganglion cells (Bye et al., 2013). 
There are separate channels for detecting the luminance and processing colour, 
they are called ON and OFF channels. In response to light, all photoreceptors 
hyperpolarize, hyperpolarization can either pass unchanged in the OFF bipolar 
cells or it can either be depolarized in the ON bipolar cells. The ganglion cells 
have a circular receptive field that allows convergence of the signals from 
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different areas of the retina. The receptive field have a centre surround 
organization, ON-centre ganglion cells are excited at the centre and inhibited in 
the periphery, while OFF-centre ganglion cells are inhibited in the centre and 
excited in the periphery. Rods are only connected to depolarizing bipolar cells 
(ON). 
 
The neural circuit output through S-cone have two pathways, either ‘branch 1’: 
straight through to small bistratified ganglion cell pathway or ‘branch 2’: through 
horizontal cells to the terminals of adjacent L and M cones which then output to 
ganglion cells via L and M specific bipolar cells (Figure 1-5). The presence of L or 
M cones in the center of the receptive field, together with input from either the 
ON or OFF ganglion cell will result the four possible combinations of hue 
perception involving contribution from the three different types of cones in the 
following manner: blue = (S+M)-L; yellow = L-(S+M); red = (S+L)-M and green = 
M-(S+L).  
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Figure 1-5: The Retinal circuits based on known anatomical connections. These 
circuits would give rise to signals matching the spectral signatures of human 
perception following addition of a third cone type. ‘Branch 1’ indicates the 
straight-through S-cone output to the small bistratified ganglion cell pathway ; 
‘branch 2’ is a second known anatomical connection that may provide S-cone 
output to the midget ganglion cell pathway via H2 horizontal cells. The addition 
of M cones changes the ‘surrounds’ of small bistratified ganglion cell receptive 
fields. Both the ‘center’ and ‘surround’ of ganglion cell receptive fields become 
altered by the addition of M cones, splitting the pre-existing blue-yellow circuit 
into two organizations with distinct spectral response properties, one for blue-
yellow and one for red-green (inset). (Neitz, Jay, Adler's Physiology of the Eye, 
Chapter 34 ‘colour vision’, 648-654). 
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1.4 POST-RETINAL PATHWAYS 
Nerve fibres converge at the optic disc to leave the eye through the optic nerve 
to reach the optic chiasm, where the nerve fibres from the nasal retina 
decussate to enter the optic tract of the opposite side; whereas the temporal 
fibres remain uncrossed.  The fibres continue through the optic tracts which 
carry the signals to the dorsal lateral geniculate nucleus in the brain (dLGN). 
The dLGN has a laminated structure and consists of six curved layers of cells. The 
layers of cells are separated by white bands of optic nerve fibres; they are 
numbered 1 to 6. The nerve fibres that cross the midline terminate in layers 1, 
4 and 6, while the fibres that do not cross terminate in layers 2, 3 and 5. 
The optic radiations are formed of nerve fibres that originate from the nerve 
cells in the laminae of the LGN. They terminate in the visual cortex (V1) which 
lies in the posterior part of the occipital cortex and is formed of two areas, the 
primary visual area (Brodmann’s area 17) and the secondary visual area 
(Brodmann’e areas 18 and 19). 
 
1.5 VISUAL PROCESSING OF NORMAL TRICHROMATIC COLOUR VISION 
Colour vision is one of the most important aspects of visual function. An 
individual with three classes of normally functioning cone photoreceptors is 
usually described as having normal, trichromatic colour vision. This relates to a 
process called ‘trichromacy’ in which the retina processes and conveys colour 
information starting by the light stimulation of the 3 different types of cones.  
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The trichromatic colour theory was first suggested by Thomas Young in the 18th 
century, and later developed by Hermann von Helmholtz. This theory states that 
normal colour signals require the presence of three kinds of nerve fibers in the 
retina. 
Later in 1875, Hering suggested that large number of colours is perceived by 
mixture of two opponent colours, this was called the opponent colour theory 
(Figure 1-6). It involves the formation of colour through comparison of signals 
from different cones through two channels. The RG channel that utilise the 
difference between L and M cones. The YB channel which involves comparing 
signals derived from the M and L cones to the ones received through S cones. 
The combination of three cones photopigments with their different 
photosensitivity enables the individual to process a great number of 
combinations allowing the appreciation of large number of different colours. 
(Figure 1-6). 
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Figure 1-6: Hering's opponent colours schematic diagram. A diagrammatic 
representation of opponent colours theory. The right ring shows a range of 
colours changing in small steps from green at the top clockwise to blue, red, 
yellow and back to green. The left ring shows the hypothetical contributions 
of each of the colour-opponent pairs (red vs. green, and blue vs. yellow) to the 
appearance of the corresponding colours in the right ring. Comparison from 
the M and L cone signals produce the RG channel while the YB channel is 
achieved from comparison of signals from S cone to the combined M and L 
signals. (Hering, 1920). 
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Utilising this theory and the trichromatic colour theory, in 1896 Muller proposed 
the zone theory or stage theory which is based on three different colour 
receptors that initiates three different neuronal signals that are processed and 
transformed as two sets of opponent colour signals.  
The zone theory assumes that there is three zones, in the first zone there is three 
types of cones initiating colour vision through absorption of light by 
photopigments sending electrical signals to reach the second zone. In the 
second zone colour signals are coded creating one achromatic signal and two 
achromatic signals following the opponent theory proposed by Hering. The final 
zone is located in the cortex and is responsible for interpretation of the signals 
in relation to other spatial and temporal information. (Figure 1-7) 
 
Figure 1-7: Schematic representation of Müller zone model.  First stage: L, M 
and S cone photoreceptors (top and bottom). Second stage: L-M and M-L cone 
opponency (top) and S-(L+M) and (L+M)-S cone opponency (bottom). Third 
stage: colour is achieved by summing the various cone-opponent second stage 
outputs (obtained from hhtp://www.cvrl.org). 
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In 1956 Gunnar Svaetichin proved the existence of the retinal nerve cells that 
Young suggested, these cells are sensitive to three different wavelengths. Later 
in 1980 Bowmaker & Dartnall were able to use micro-spectroscopy to measure 
the spectral transmittance of a small beam of light passing through the outer 
segment (OS) of individual cones in vitro and obtain three kinds of spectra with 
their absorbance peaks. Each of the three types of cones contains a different 
type of photosensitive pigment, which is composed of a transmembrane protein 
called opsin and a light-sensitive molecule called 11-cis retinal. Colour 
processing starts when each of these three different photosensitive pigments is 
struck by a photon with the specific wavelength to which that pigment is most 
sensitive to, this initiates a cellular response and a signal that is transmitted to 
the brain. 
 
The spectral sensitivities of the three cone classes (Figure 1-8) along with the 
spectral sensitivity of the rods, their wavelengths are as follows: rods, 496.3+/-
2.3 nm; red cones, 564 +/- 5.2 nm; green cones, 534 +/- 3.5 nm; and blue cones 
420 +/- 3.6 nm (Stockman and Sharpe, 2000). 
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Figure 1-8: Normalized absorbance of the three human cone pigments, 
indicating the relative sensitivity of the three cone types to light of different 
wavelengths (obtained from http://www.cvrl.org). 
 
More recently Berson et al., 2002 described another subtype of retinal ganglion 
cell that contains melanopsin and is photosensitive. It is believed that such 
intrinsically photosensitive cells contribute to the control of the circadian 
rhythm and its maximum spectral absorption is 484 nm. 
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2 INTRODUCTION 
2.1 DIABETES MELLITUS 
Diabetes Mellitus (DM) is one of the most serious conditions of the modern age, 
its incidence with the subsequent complications are increasing worldwide. 
According to the international diabetes federation (IDF), 415 million are affected 
with diabetes; this number is expected to rise to 642 million people by 2040. DM 
is a chronic metabolic disease that results from defects in insulin secretion, 
insulin action or both. The world health organization (WHO) issued 
recommendations for the diagnostic criteria of DM based on clinical symptoms 
such as polyuria, polydipsia and unexplained weight loss in addition to blood 
tests that show: 
1. Random venous plasma glucose concentration ≥ 11.1 mmol/l or 
2. Fasting plasma glucose concentration ≥ 7.0 mmol/l or 
3. Plasma glucose concentration ≥ 11.1 mmol/l, two hours after 75g 
anhydrous glucose in an oral glucose tolerance test (OGTT) 
There are different types of DM, the main types as identified are: 
1. Type I:  
An autoimmune condition in which the body attacks and destroys Beta 
islet cells of Langerhans in the pancreas which are insulin producing cells. 
This type affects 10% of people with diabetes.  
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2. Type 2: 
The body does not produce sufficient insulin or there is insulin resistance 
which means that different body cells are not able to respond adequately 
to normal levels of insulin. This type affects 90% of people with diabetes. 
3. Gestational diabetes: 
It develops in woman during pregnancy where the fasting glucose level is 
≥5.6 mmol/l or 2-hour plasma glucose level ≥7.8 mmol/l. 
 
Complications of diabetes: 
Hyperglycaemia as well as hypoglycaemia have damaging effect on 
different cells of the body systems leading to macrovascular 
complications (coronary artery disease, peripheral arterial disease, and 
stroke) and microvascular complications (Diabetic nephropathy, 
neuropathy, and retinopathy).  
 
2.2  DIABETIC RETINOPATHY 
 
2.2.1  DEFINITION OF DIABETIC RETINOPATHY 
 
Diabetic retinopathy (DR) is the most common and serious ocular complication 
of diabetes; it is a chronic progressive potentially sight threatening disorder 
caused by changes in the retinal microvasculature which are brought about by 
prolonged hyper and hypoglycaemia. DR is accelerated by other diabetes 
mellitus related factors such as duration, control and associated systemic 
conditions such as Hypertension and Dyslipidaemia (Van Leiden et al., 2002). 
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2.2.2  CLASSIFICATION OF DIABETIC RETINOPATHY 
DR is diagnosed and graded according to the extent of microvascular changes 
observed on fundus examination. This is now done through diabetic retinal 
screening programmes in different parts of the country through the National 
Health Service (NHS). The United Kingdom (UK) has a well implemented 
screening programme that offers screening to 80.1% of its diabetic population 
with 73.5% actually undertaking the screening tests (NHS Diabetic Eye Screening 
Programme, 2012). All eligible patients have their fundus photographs taken, 
this is later reviewed by a grader who is able to quantify the severity of changes 
and refer to a specialist when needed.  
There are two widely used forms for DR grading in the UK, one of which has been 
adopted from the National Screening Committee (NSC) (Harding et al., 2003) 
and used in population screening programmes, and another which is based on 
the Early Treatment Diabetic Retinopathy Study (ETDRS) that depend on 
modifications from the Diabetic Retinopathy Study (DRS) and mainly used in 
clinical settings. There are similarities between both forms of classifications with 
focus on two aspects, retinopathy and maculopathy. 
 
2.2.2.1  Retinopathy 
Retinopathy is classified according to the vascular changes present in the retina. 
Table 2-1, summarises the classification criteria according to the NSC grading 
criteria and table 2-2 summarises classification criteria according to the ETDRS.  
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2.2.2.2  Maculopathy 
Maculopathy is a form of retinopathy that affects the macula and is also known 
as diabetic Macular Oedema (DMO). It is classified according to the NSC into 
presence (M1) or absence (M0) of maculopathy. The ETDRS define clinically 
significant Macular Oedema (CSMO) by the presence of the following: 
 Retinal thickening within 500 µm of the center of the fovea 
 Hard, yellow exudates within 500 µm of the center of the fovea with 
adjacent retinal thickening 
 At least 1 disc area of retinal thickening, any part of which is within 1 disc 
diameter of the center of the fovea 
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Table 2-1: National Screening Committee grading criteria (Harding et al., 
2003). 
 
 
 
R0              None 
R1              Background                             Microaneurysm(s) 
                                                                      Retinal haemorrhage(s) ± any exudate    
R2              Pre-proliferative                     Venous beading 
                                                                      Venous loop or reduplication 
                                                                      Intraretinal microvascular abnormality (IRMA)  
                                                                      Multiple deep, round or blot haemorrhages 
                                                                     Cotton wool spots (CWS) 
R3              Proliferative                            New vessels on disc (NVD) 
                                                                     New vessels elsewhere (NVE) 
                                                                     Pre-retinal or vitreous haemorrhage 
                                                                     Pre-retinal fibrosis ± tractional retinal detachment 
M0            Nil present 
M1            Maculopathy                          Exudate within 1 disc diameter (DD) of the centre of              
                                                                     the fovea 
                                                                    Circinate or group of exudates within the macula 
                                                                    Retinal thickening within 1DD of the centre of the fovea 
                                                                    (if stereo available) 
                                                                    Any microaneurysm or haemorrhage within 1DD of the 
                                                                    Centre of the fovea only if associated with a best visual 
                                                                    acuity of ≤ 6/12 (if no stereo)            
 
PHOTOCOAGULATION (P)                    Focal/grid to macula 
                                                                   Peripheral scatter     
UNCLASSIFIABLE (U)                              Ungradable / unobtainable 
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Disease Severity Level  
 
Findings Observable upon Dilated 
Ophthalmoscopy  
Mild non-proliferative retinopathy  At least one microaneurysm, and definition 
not met for moderate nonproliferative 
retinopathy, severe nonproliferative 
retinopathy, early proliferative retinopathy, or 
high-risk proliferative retinopathy (see below)  
Moderate non-proliferative retinopathy  Haemorrhages and/or microaneurysms ≥ 
standard photograph 2A; and/or soft 
exudates, venous beading, or intraretinal 
microvascular abnormalities definitely 
present; and definition not met for severe 
nonproliferative retinopathy, early 
proliferative retinopathy, or high-risk 
proliferative retinopathy (see below)  
Severe non-proliferative retinopathy  Soft exudates, venous beading, and 
intraretinal microvascular abnormalities all 
definitely present in at least two of fields four 
through seven; or two of the preceding three 
lesions present in at least two of fields four 
through seven and haemorrhages and 
microaneurysms present in these four fields, 
equalling or exceeding standard photo 2A in at 
least one of them; or intraretinal 
microvascular abnormalities present in each of 
fields four through seven and equalling or 
exceeding standard photograph 8A in at least 
two of them; and definition not met for early 
proliferative retinopathy or high-risk 
proliferative retinopathy (see below)  
 
Early proliferative retinopathy (i.e., 
proliferative retinopathy without Diabetic 
Retinopathy Study high-risk characteristics)  
 
New vessels; and definition not met for high-
risk proliferative retinopathy (see below)  
 
High-risk proliferative retinopathy 
(proliferative retinopathy with Diabetic 
Retinopathy Study high-risk characteristics)  
 
New vessels on or within one disc diameter of 
the optic disc (NVD) ≥ standard photograph 
10A* (about one-quarter to one-third disc 
area), with or without vitreous or preretinal 
haemorrhage; or vitreous and/or preretinal 
haemorrhage accompanied by new vessels, 
either NVD < standard photograph 10A or new 
vessels elsewhere (NVE) ≥ one-quarter disc 
area  
Table 2-2: Classification of diabetic retinopathy in the early treatment of 
diabetic retinopathy study (ETDRS report 7, 1991). 
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2.2.3  DIABETIC MACULAR OEDEMA (DMO) 
DMO is one of the most serious squeals of DR. It affects 20% of patients with DR 
(Yau et al., 2012) and is caused by a breakdown of the outer blood retinal 
barriers secondary to an inflammatory process that releases prostaglandins, 
leukotrienes and vascular endothelial growth factor (VEGF) (Bhagat et al., 2009). 
This causes an accumulation of extracellular fluid within the inner and outer 
retinal layers, creating cystoid spaces that can extend to affect the whole retinal 
thickness. This leads to displacement of the retinal neuronal components with 
subsequent temporary or permanent visual loss (Pelosini et al., 2011). 
Implications and management of DMO are discussed in more details later in the 
thesis in chapter 5. 
 
 
2.2.4   EPIDEMILOLOGY OF DIABETES AND DIABETIC RETINOPATHY 
2.2.4.1 Incidence and prevalence of diabetes 
The number of people suffering from diabetes is on the rise and it is estimated 
that 220 million people have diabetes worldwide (WHO, 2010). According to a 
recent DR guidelines report published by the Royal College of Ophthalmologists 
it is estimated that 1 in every 25 people suffer from diabetes in the UK 
(https://www.rcophth.ac.uk). 
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2.2.4.2  Incidence & prevalence of diabetic retinopathy 
It is estimated that worldwide there are more than 100 million people with DR 
and of these at least 30 million people are at risk of developing severe sight-
threatening retinopathy (Yau at al., 2012). In 2004, Resnikoff et al. reported that 
DR is the leading cause of visual impairment amongst the working age 
population in the developed world. In the UK, it is one of the three most 
common recorded causes of certification as sight impaired (Bunce et al., 2010). 
In a recent study about prevalence and causes of vision loss in high-income 
countries and in Eastern and Central Europe: 1990-2010 (Bourne et al., 2014), 
DR was the fifth most common cause of moderate and severe vision impairment 
(MSVI) (presenting visual acuity <6/18 but ≥3/60 in the better eye) and blindness 
(presenting visual acuity <3/60).  
 
The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), a large 
population study on DR conducted in the USA found that the overall 10-year 
incidence of retinopathy was 74%. 64% of people with retinopathy at baseline 
showed progression of retinopathy on follow ups and 17% progressed to 
develop proliferative retinopathy (Varma, 2008). After 25 years follow up, in the 
type 1 diabetes cohort, almost all patients (97%) developed retinopathy over 
time with 43% developing proliferative retinopathy and 29% developing macular 
oedema (MO).  
In the last 15 years of the study there was decline in the yearly incidence and 
progression of DR rate compared to the first 10 years of the study, especially in 
people with recently diagnosed diabetes (Klein et al., 2009). This demonstrates 
the positive impact of improved diabetes management in developed countries 
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during the past two decades. Since the introduction of the nationwide DR 
screening programmes in England and Wales and for the first time in at least the 
last five decades, DR is now the second cause of certifiable blindness among the 
working age adults (Liew at al., 2013). 
In the Liverpool Diabetic Eye Study, Younis et al., 2002 studied the prevalence of 
diabetic eye disease in patients entering a systematic primary care-based eye 
screening programme. They recruited 831 subjects with type 1 diabetes and 
7231 subjects with type 2 diabetes.  In the type I group, 45.7% had non-
proliferative diabetic retinopathy (NPDR), 3.7% had proliferative diabetic 
retinopathy (PDR) and 16.4% had sight threatening eye disease (STED). For the 
type 2 group, 25.3% had NPDR, 0.5% had PDR and 6.0% had STED. 
The United Kingdom Prospective Diabetes Study (UKPDS) ran for twenty years 
(1977-1997) and recruited 5,102 patients with newly diagnosed type 2 diabetes. 
As part of this study, Kohner et al., 1998 reported the incidence of retinopathy, 
defined as microaneurysms or worse lesions in at least 1 eye, in 39% of men and 
35% of women, while marked retinopathy with cotton wool spots or intraretinal 
microvascular abnormalities was present in 8% of men and 4% of women from 
a total of 2964 of Caucasian patients included in the study. The UKPDS also 
showed that intensive blood-glucose control with sulphonylurea or insulin 
therapy reduced the risk of any diabetes-related endpoint by 12% and 
microvascular disease by 25%. The post-trial monitoring showed continuing 
benefit of earlier improved glucose control with reduction in diabetes related 
endpoint (9%, P=0.04) and microvascular disease (24%, P=0.001) as well as 
continuing benefit of earlier metformin therapy, with maintenance of the 
relative risk reductions reported for any diabetes related endpoint (21%, 
P=0.013). 
 38 
 
2.2.5   PATHOPHYSIOLOGY OF DIABETIC RETINOPATHY 
DR is caused by a chronic exposure to hyperglycaemia and other risk factors such 
as hypertension which seems to initiate a cascade of biochemical and 
physiological changes that are responsible for the retinal microvascular damage 
(Figure 2-1).  
 
 
Figure 2-1: Diagrammatic representation of pathophysiology of diabetic 
retinopathy. Hyperglycaemia instigates a cascade of events leading to retinal 
vascular endothelial dysfunction. Resultant retinal ischaemia and increased 
vascular permeability, augmented by hypertension, are two key common 
pathways underlying development of vision-threatening diabetic retinopathy. 
AGE=advanced glycation end-products. PKC=protein kinase C. RAS=renin-
angiotensin system. CA=carbonic anhydrase. VEGF=vascular endothelial 
growth factor. GH-IGF=growth factor–insulin growth factor. PDR=proliferative 
diabetic retinopathy. VH=vitreous haemorrhage. RD=retinal detachment 
(Cheung et al., 2010). 
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As response to the hyperglycaemic state, inflammatory mediators are 
upregulated triggering responses that cause abnormal leucocyte-endothelial 
interactions resulting in microvascular damage. The structural changes observed 
in retinal vasculature starts with arteriolar dilation in response to the increased 
capillary pressure this result in leakage (oedema and hard exudates) and rupture 
(haemorrhages). 
 
 
2.2.5.1 Vascular changes vs. neuronal changes 
The understanding of the mechanisms involved in developing DR have been 
increasing over the past few decades. It is now accepted that DR is not just the 
result of microvascular changes but it also involves neuronal retinal changes 
(Antonetti et al, 2006). There have been many studies that used 
electroretinography (Wachtmeister at al., 1978) (Holopigian et al., 1997) 
(Fortune et al., 1999), contrast sensitivity (Della Sala et. al., 1985) (Di Leo et al., 
1992) (safi et al., 2017) (Nerianuri et al., 2017) , retinal senstivity (Montesano et 
al., 2017) (Nerianuri et al., 2017) and CV tests to demonstrate that neuroretinal 
function is compromised before the onset of vascular changes are observed. 
The retina is vascularized neural tissue, not just a network of blood vessels. It 
remains unclear whether the sequence of events starts in blood vessels or 
neural cells. Inflammation is a prominent component of DR and is a natural 
response to continuous cellular stress. It is characterized by increased vascular 
permeability, oedema, cytokine and chemokine expression including vascular 
endothelial growth factor (VEGF), interleukin-1β and tumour necrosis factor-α 
(TNF-α). Although these normal inflammatory factors serve as an adaptive 
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mechanism to maintain neuronal function and represent an attempt to limit the 
retinal damage over time they cause tissue destruction and neovascularization 
with retinal damage (Seigel et al., 2000; Barber at al., 2001; Gariano et al., 2005). 
 
2.2.5.2  Risk factors 
Risk factors for developing DR can be divided to two subgroups, non-modifiable 
and modifiable factors which are described below. 
 
2.2.5.2.1  Non-modifiable risk factors 
1. Ethnic origin: 
The Diabetic Retinopathy in Various Ethnic groups in UK (DRIVE UK) study 
(Sivaprasad et al., 2012) was the largest cross-sectional study on the prevalence 
of DR in the various ethnic groups with diabetes in the UK. It showed that the 
prevalence of any retinopathy in type 2 diabetes is highest in people of 
African/Afro-Caribbean descent compared to South Asians or white Europeans. 
In type 2 diabetes, the prevalence of any DR was 38.0% in white Europeans 
compared to 52.4% in African/Afro-Caribbeans and 42.3% in South Asians. 
Similarly, sight threatening DR was also significantly more prevalent in Afro-
Caribbeans (11.5%) and South Asians (10.3%) compared to white Europeans 
(5.5%). 
 
A community-based cross-sectional study (sub-study of the UK Asian Diabetes 
Study (UKADS)) looked at people of South Asian ethnicity in Coventry-England. 
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It recruited 1035 patients with type 2 diabetes: 421 of South Asian and 614 of 
white European ethnicity. Results showed that people with a south Asian ethnic 
origin were more likely to have DR than white European people. DR was 
detected in 414 (40%) patients (189 South Asian (45%) versus 225 white 
European (37%); P = 0.0078). Sight-threatening retinopathy was detected in 142 
(14%) patients (68 South Asian (16%) versus 74 white European (12%); P = 
0.0597) (Raymond et al., 2009). 
 
2. Duration and age at onset: 
The duration of diabetes is a strong predictor for the development and 
progression of retinopathy (Fong et al., 2004). The development of DR has a 
linear relationship with the duration of diabetes, so the longer the duration of 
diabetes the higher the prevalence of DR (Wong et al., 2009). 
The Wisconsin Epidemiology Study of Diabetic Retinopathy (WESDR) showed 
that the 4-year incidence of developing proliferative retinopathy in the younger-
onset group increased from 0% during the first 5 years to 27.9% during years 
13–14 of diabetes and after 15 years, the incidence of developing PDR remained 
stable. It also showed that in patients diagnosed before age 30 years, 97% had 
retinopathy and 25% had PDR at 15 years post diagnosis (Klein et al., 1984). 
  
3. Puberty: 
When the onset of diabetes is at puberty, the risk of developing DR is higher, 
taking into consideration that there are several physiological and psychosocial 
factors that can disrupt glycaemic control. The Diabetes Study Group of the 
Italian Society of Pediatric Endocrinology and Diabetology (ISPED) found that the 
prevalence of DR was higher in pubertal than in prepubertal patients, both for 
any grade DR (71% vs. 40%, P = 0.002) and for mild or more severe DR (P = 0.005). 
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Diabetes duration after menarche is associated with 30% excess risk of 
retinopathy compared with diabetes duration before menarche (WESDR) (Klein 
et al., 1990). It has also been suggested that prepubertal years might offer some 
protection against developing DR (Olsen et al., 2004). 
 
 
2.2.5.2.2  Modifiable risk factors 
1. Diabetic control: 
The Diabetes Control and Complications Trial (DCCT, 1982-93) compared the 
effects of two treatment regimes, standard therapy and intensive control on the 
complications of diabetes, it demonstrated that achieving glycaemic levels close 
to the non-diabetic range by intensive treatment reduced the risk of developing 
DR by 76%. This was followed by the Epidemiology of Diabetes Interventions and 
Complications study (EDIC, 1994-2006) which investigated the long-lasting 
effects of the previously assigned therapies. One of the most important 
conclusions of the study was that the salutary effect of intensive therapy persists 
for at least 10 years after differences in glycaemia between the original intensive 
and conventional therapy groups have disappeared, this have been named 
imprinting or metabolic memory. 
 
The UK Prospective Diabetes Study (UKPDS, 1998) showed that intensive blood 
glucose control reduced the risk of diabetic complications, the greatest effect 
being on microvascular complications by 25%. It also demonstrated that for 
every percentage point decrease in Glycosylated Haemoglobin, Type A1C 
(HbA1C) there was a 35% reduction in the risk of microvascular complications. 
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2. Blood pressure: 
The UKPDS also studied the influence of tight blood pressure control with an 
ACE inhibitor or a beta blocker over a median of 8.4 years. It showed reduced 
risk of both microvascular and macrovascular disease, where 34% had reduction 
in progression of retinopathy and 47% reduced risk of deterioration in visual 
acuity of three lines after 10 mmHg systolic and 5 mmHg diastolic reduction in 
blood pressure. 
Gallego et al., 2008 provided evidence for the relationship between elevated 
blood pressure and risk of retinopathy in young people with type 1 diabetes. 
They examined 1869 patients with type 1 diabetes and a median age of 13.4 
years. Retinopathy developed in 36% of participants. The risk was higher for 
developing DR in patients who had higher systolic and diastolic blood pressures. 
  
3. Dyslipidaemia: 
Dyslipidaemia has also been linked to the pathogenesis of DR (van Leiden et al., 
2002; Klein et al., 2002). Several studies have studied the effect of lipid lowering 
medications on the pathogenesis of DR. Sen at al. (2002) conducted a double-
blind randomized placebo-controlled trial and concluded that simvastatin 
significantly retards the progression of retinopathy in diabetic patients although 
there was limited to no improvement of visual acuity in patients receiving the 
treatment. 
The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, a 
randomised controlled trial with 9795 participants aged 50-75 years, found that 
Fenofibrate, a lipid modifying agent, reduced the need for laser treatment (5·2% 
vs 3·6%, p=0·0003) (Keech et al., 2005).  
These findings were also supported by the Action to Control Cardiovascular Risk 
in Diabetes (ACCORD) study which showed that over a 4-year period there was 
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a 40% reduction in the odds of progression of retinopathy in a subgroup having 
Fenofibrate in combination with a statin, compared to simvastatin alone (Chew 
et al., 2010). 
However, the Collaborative Atorvastatin Diabetes Study (CARDS) did not find 
atorvastatin to be effective in reducing DR progression (Thomason et al., 2004; 
Colhoun et al., 2004). 
 
2.2.6   MANAGEMENT AND TREATMENT OF DIABETIC RETINOPATHY 
A systematic review and met-analysis by Cheung at al., 2009 looked at the rates 
of progression in DR during different time periods. They included 28 studies 
published between 1975 and February 2008. They found that participants in 
1986–2008 studies had lower proportions of PDR and non-PDR at all-time points 
than participants in the 1975–1985 studies. In studies reporting outcomes at 10 
years, rates for PDR were 11.5% in 1975–1985 versus 6.6% in 1986–2008 and for 
severe vision loss (SVL), corresponding rates were 6.0% versus 2.6%, 
respectively. 
This data is supportive of the premise that in recent years there has been decline 
in the rates of DR development due to the improved screening and management 
of diabetes. 
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2.2.6.1  Management of diabetic retinopathy 
The aim of the screening process and management of DR is the prevention, 
detection and treatment of sight-threatening maculopathy and proliferative 
retinopathy. 
Systematic population screening for DR has been implemented in the UK several 
years ago (NHS diabetic eye screening programme, 2013). Screening is 
conducted using high-definition fundus photography which is evaluated by 
graders that applies strict grading criteria, as discussed previously in section 2.2. 
Table 2-3 summarizes the NSC management criteria. 
 
Those patients with referable retinopathy, i.e. maculopathy, moderate, severe 
or PDR are usually referred within set time limits to the hospital eye service for 
further management as required. Not all patients referred to hospital will 
require treatment, regular monitoring and adequate control of diabetes and 
other risk factors such as blood pressure and lipid levels, can sometimes be 
enough to control DR changes and reduce the risk of progression to diabetic 
maculopathy. This requires a multi-disciplinary team approach with liaison 
between the DR services, ophthalmologists, diabetologists and general 
practitioners. 
 
The mainstay for treating proliferative DR remains to be the pan-retinal laser 
photocoagulation (PRP). In some cases of advanced PDR, with vitreous 
haemorrhage and tractional retinal detachment, vitrectomy should be 
considered. As for DMO, several treatment modalities are currently available- as 
discussed in section 5.1 - focal or grid macular laser, still have a role in treating 
localized MO, although for diffuse MO intravitreal injections such as VEGFs 
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inhibitors or steroids are more effective and are now available and licensed by 
the National Institute for Health and Care Excellence (NICE) for treating DMO. 
 
 
RETINOPATHY (R)   
R0                                            Annual screening 
R1                                            Annual screening, inform diabetes care team 
R2                                            Refer to hospital eye service 
R3                                            Fast-track referral to hospital eye service 
MACULOPATHY (M) 
M0                                           Annual screening 
M1                                           Refer to hospital eye service 
PHOTOCOAGULATION (P) 
P1                                             New screen — refer to hospital eye service 
                                                 Quiescent post treatment — annual screening 
OTHER LESIONS (OL)           Refer to hospital eye service or inform primary physician 
UNGRADABLE (U)                Media opacity hospital eye service 
UNSCREENABLE/UNOBTAINABLE 
                                      Poor view but gradable on biomicroscopy, refer hospital eye service 
                                      Unscreenable, discharge, inform GP  
                                      (Option to recall for further photos if purely technical failure) 
Table 2-3: National Screening Committee management criteria / action 
(Harding et al., 2003).  
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2.3  DIABETIC RETINOPATHY AND COLOUR VISION 
In recent years, our understanding of DR has changed and it is now accepted 
that DR not only affects the retinal vasculature, but it also affects the neural 
retina. Hence, more studies have started investigating the neurodegenerative 
changes of DR. Those changes are usually assessed mainly by measuring any 
reduction in chromatic sensitivity or / and by using electrophysiological 
diagnostic tests such as full-field or multifocal electroretinography (ERG). 
 
2.3.1  Retinal neurodegeneration in diabetes 
Several changes are observed in neuronal retina in diabetes, some of those 
changes might even precede the development of signs that can be seen on 
examining the retina in DR. The mechanisms by which such changes occur are 
not fully understood, and although several theories exist, none have succeeded 
in giving a full explanation of the exact mechanisms involved. The following 
section lists and discusses the most common theories put forward to account 
for the neurodegenerative changes and events that might happen in the retina 
of a diabetic person. 
 
2.3.1.1 Inflammation: 
Inflammation is one of the key processes involved in DR (Racquel et al., 2005). 
Under normal conditions microglia which are associated with retinal neurones 
are regulated, but under the stress caused by diabetes, the microglia are 
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activated and start to release inflammatory cytokines (Schroder et al., 1991). 
This leads to the start of an inflammatory process that leads to the development 
of DR. The events that follow cause the blood–retinal barrier to degrade and in 
turn this may affect the normal functioning of the retina. These events include: 
increased vascular permeability, cellular infiltration, release of cytokines and 
growth factors including IGF-1, Interleukin-1, TNF and VEGF. These factors 
provide neurotrophic functions and are released in an attempt to repair the 
retinal cells and to help overcome the stress (Seigel et al., 2000; Barber at al., 
2001; Gariano et al., 2005). The abundant release of these factors results in loss 
of the integrity of the blood-retinal barrier, progressive vascular damage and 
neuronal cell loss seen in progressive stages of DR (Antonetti et al., 2006). 
 
2.3.1.2 Apoptosis 
Several studies suggested that diabetes causes chronic loss of inner retinal 
neurones by increasing the frequency of apoptosis. This was demonstrated by 
Barber et al. (2003) in a study which examined animal models and post-mortem 
human tissue and found that the number of apoptotic nuclei in retinal neurons 
and glial cells was elevated after inducing diabetes. After a period of intensive 
treatment with insulin, the amount of apoptosis was however reduced. There 
are also reports from  biochemical studies which show that the expression of 
Bax (BCL-2 associate X protein), a protein associated with degenerative diseases 
and caspases,  an enzyme involved in apoptosis are both increased in the retinas 
of diabetic rats (Podesta et al., 2000; Mohr et al., 2002). 
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Another factor that plays a role as well in the process of apoptosis is the 
decrease in the anabolic stimulus provided by insulin due to the reduction in 
number of insulin receptors (Yi et al., 2005). It is known that insulin plays an 
important role in supporting retinal neurones and vascular cells (Barber et al., 
2001; Kondo et al., 2003). The DCCT study demonstrated that intensive 
treatment with insulin reduces the amount of apoptosis and reduces the risk of 
developing retinopathy (DCCT, 1982-93). These findings suggest that the 
increase in apoptosis within the neural retina is an important factor in the onset 
and progression of the DR process. 
 
2.3.1.3  Glutamate Excitotoxicity 
Neuronal cells plays an important role in converting neurotoxin glutamate into 
less toxic glutamine which explains why excessive levels of glutamate are usually 
seen in the central nervous system when there is neuronal cell loss (Gillies et al., 
2000). In the retina, diabetes reduces the ability of the retina to convert 
neurotoxic glutamate into less toxic glutamine due to the reduction of the glial 
enzyme glutamine synthetase (Lieth et al., 1998). There is also an associated 
reduction in the activity of glutamate transporters in Muller cells leading to 
elevated concentration of glutamate in the extra cellular fluid (Li and Puro, 
2002). This observation also explains the detection of increased levels of 
glutamate in the vitreous in diabetic subjects (Ambati et al., 1997; Lieth et al., 
1998). Neuronal apoptosis observed in the retina in patients with diabetes may 
therefore be caused by chronic exposure to the glutamate excitotoxicity (Barber 
et al., 2001). 
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Over the years there have been many studies to investigate the relationship 
between CV loss and diabetes, but the majority of them are using CV tests that 
were primarily designed to detect hereditary CV loss rather than pathological 
loss. In addition, none of the tests has the ability to quantify reliably the severity 
of red / green (RG) and yellow / blue (YB) colour vision loss.  This is important 
when the aim is to follow up patients with diabetes and to detect progression 
or even improvement as we will discuss later in this thesis (chapter 6). 
 
The agreement among the different studies is that there is a degree of CV loss 
in diabetic patients, but that the wide variation in results makes it difficult to 
establish how CV loss correlates with other parameters that are used routinely 
for screening and examining diabetic patients such as VA and OCT. Also there is 
no agreement as to whether these CV losses are correlated to different diabetes 
related factors such as grade of retinopathy, duration or control.  
 
In 1982 Maloney and Drury studied 66 patients (132 eyes) with type I diabetes 
for CV loss using the FM-100 hue test and reported high error scores in 88 eyes 
(56.7%). Several other studies followed (Green et al., 1985; Bresnick et al., 1985; 
Roy et al., 1986; Trick et al., 1988; Tregear et al., 1994). In these studies, the FM 
100-Hue error scores showed no correlation with age, sex, age of onset, 
duration of diabetes, metabolic control or with the degree of retinopathy. 
 
However not all studies have reported similar findings. For example, Roy et al., 
(1984) studied 12 type 1 diabetics and found a correlation between the FM-100 
error score and the degree of retinopathy, but not with fasting blood sugar. 
Ismail & Whitaker (1998), reported that the mean error score was increased in 
subjects with diabetes when compared with normal subjects, and that the level 
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of the mean error score increased with the severity of DR. These results have 
since been replicated by other studies such as Fong et al., (1999) and Barton et 
al., (2004) which studied patterns of hue discrimination impairment among 2701 
of the diabetic patients enrolled in the ETDRS. Fong et al., reported that 
approximately 50% of the patients had CV scores worse than 95% of the normal 
population. They found that hue discrimination was associated with MO 
severity, age and neovascularization. In the Barton et al. study, they were able 
to detect 13 patterns of impaired hue discrimination and reported losses in YB 
axis that correlated with the severity of DR. 
 
In a more recent study, Feitosa-Santana et al., (2006) investigated CV in 32 
subjects with type II diabetes without DR and 20 age matched controls using the 
Farnsworth D-15 and Lanthony D-15d tests and employed triadic procedure that 
enabled detection of very mild CV impairment. Results were constructed in two-
dimensional RG and YB perceptual opponent systems. The authors found that 
the colour space configurations were compressed along the YB as well as RG 
axes in the diabetic subjects which they attributed to the reduced photoreceptor 
sensitivity. 
 
Another recent study used a computerized CV test (Arden colour contrast test) 
(Al Saeidi et al., 2013) to evaluate its efficacy in detection of DMO. The authors 
examined 42 diabetic patients with and without MO, they found that YB loss was 
more pronounced than RG loss and correlated with retinal thickness on the 
Optical Coherence Tomography (OCT). 
 
O’Neill-Biba et al., (2010) used the CAD test on 7 diabetic subjects with no or 
mild DR to demonstrate that measurement of reduced chromatic sensitivity 
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along the RG and YB spectrum can provide a sensitive measure of the functional 
changes observed in DR. Their results showed almost equal RG and YB losses in 
both type I and type II diabetic subjects, there was no correlation to the duration 
of the disease and/or the absence of retinopathy. These findings agreed with 
other studies that suggested that chromatic sensitivity loss can precede 
structural changes in the retina (Hardy et al. 1992; Kurtenbach et al., 1999; Ong 
et al., 2003). 
 
Although DR is diagnosed by visual fundus examination, it has become more 
evident as research progresses and more studies are conducted, that the 
functional changes taking place in the retina of a diabetic patient precede visible 
structural changes and that neuroretinal function is compromised before the 
vascular changes are observed. Hence CV may be good predictor for evaluation 
of such functional changes, allowing earlier intervention. When coupled with 
better diabetic control, the earlier intervention may reduce the rate of diabetes 
progression and related complications. The outcome is a better quality of life 
and reduced economic burden that accompanies the care for DR patients. 
 
2.3.2   Colour vision tests 
This section describes some of the CV tests and results reported in earlier 
studies. The latter were conducted mostly during the last decade and used a 
variety of CV tests to investigate the relationship between diabetes and CV loss. 
Other studies that aimed to detect neurodegenerative changes using alterations 
in the ERG will also be reviewed. 
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In the current study, chromatic sensitivity was measured using the Colour 
Assessment and Diagnosis (CAD) test which quantifies the severity of CV loss in 
a simple and effective way. The test enables accurate assessment of both RG 
and YB loss (Barbur and Rodriguez-Carmona, 2015) of chromatic sensitivity. The 
CAD test will be described in more details in section 3.2. The majority of other 
colour vision tests fail to quantify accurately the severity of colour vision loss 
and were designed mostly to screen for congenital colour deficiency.  
 
2.3.2.1 Pseudoisochromatic test plates 
The most common is the Ishihara colour screening test. It was first published in 
1917; it is useful in screening for subjects with congenital colour deficiency 
(Belcher et al., 1958). The subject is presented with a series of colour plates with 
either numbers or convoluted lines embedded within a background of dots that 
vary in size, luminance and chromaticity.  There are several editions available 
which contain 24 and 14 plates, however the standard edition contains 38 
plates, 25 of which contain numerals (single or double-digit numbers), the 
remaining 13 plates are intended for examination of nonverbal subjects, where 
the subject is required to trace the pathway of convoluted lines. Normal 
trichomats will be able to see the correct numbers but an individual with colour 
deficiency will either fail to distinguish the number or will see different number. 
For example in hidden digits plate, normal trichomat will fail to see a number 
while a colour deficient subject might see a number. (Figure 2-2). 
 
Errors made by CV deficient subjects are considered to be typical while errors 
made by normal trichomats are considered non-typical errors. Birch and 
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McKeever, 1993 described the non-typical errors made by normal trichomats as 
‘misreadings’, it is attributed to the subject perceiving a loop of the serif as being 
complete rather than incomplete (for example, a ‘5’ may be interpreted as a ‘6’ 
or ‘3’ as ‘8 ’. The misreading is related to the strength of chromatic signal which 
means that the weaker the perceived chromatic signal in the test plate, the 
higher the probability of confusions or misreading (Rodriguez-Carmona et al., 
2012). 
4 or less errors are required for a normal trichomate to pass the test (Birch, 
2001). Reducing the number of errors means increasing the sensitivity of the 
test but even then, if the pass score is set at 3 or less errors this will mean that 
10% of deutans and 1%protans will also pass the test. If errors are not allowed, 
19% of normal trichomats will fail the 38 plates edition with at least one error. 
This makes the outcome of the test not specific and it fails to give accurate 
measure of the severity of CV loss.   
 
 
 
 
Figure 2-2: Illustration of the Ishihara Pseudoisochromatic plate test (38 
plates edition). (A) Transformation plate, normal trichomats would see the 
number ‘8’ while a colour deficient subject would see it as ‘3’, (B) Vanishing 
plate, most colour deficient subjects would not see the number ‘73’, (C) 
Hidden digit plate, normal trichomats would fail to see a number while a 
colour deficient subject might see a number ‘5’. 
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2.3.2.2 Arrangement tests 
 
Arrangement tests utilize coloured caps with different hues. The subject is 
required to arrange the caps in order of hue. The test scores are reported in the 
form of error score that is derived from the number and pattern of errors made 
during the arrangement. 
 
2.3.2.2.1  Farnsworth-Munsell Hue test 
The FM-100 hue test aims to evaluate the subject’s hue discrimination ability. 
The observer is required to arrange colour samples according to hue, lightness 
and saturation. There are 2 versions of the test, the Farnsworth-Munsell 100 
(FM-100) hue test which has 85 colour samples and the Farnsworth- 
dichotomous test (D-15) which has 15 coloured samples. The Farnsworth-
Munsell 100-Hue is formed of four 21 or 22-cap sets (Figure 2-3). The subject is 
instructed to start with the marked cap and arrange the rest in order according 
to their colour for each of the boxes. The test is scored by calculating error score 
and plotting graphical representation using the numbers on the back of the caps. 
Hue discrimination ability is measured as the square root of the total error score 
and the type of CV deficiency is established by interpreting a graphical 
illustration of the results (Figure 2-4). There is no direct correlation between 
severity of a colour defect and the error score (Birch, 1989).  Subjects with mild 
or moderate colour deficiency would be able to pass the test due to the colour 
difference between adjacent caps (Birch, 2001).  The performance on the test is 
influenced both by the illumination used as well as the skill, comprehension, and 
motivation of the subject (Farnsworth, 1957). 
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Figure 2-3: Illustration of the Farnsworth-Munsell 100 (FM-100) hue test. 
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Figure 2-4: Graphical representation of the D-15 cap arrangements. (A), (B), 
(C): normal subjects, (D): a protan subject, (E): a deutan subject, (F): a tritan 
subject (adapted from Vingrys and King-Smith, 1988). 
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2.3.2.2.2  Lanthony’s Desaturated Panel 15 test  
This is another arrangement test; it has 15 colour samples which are less 
saturated than the Farnsworth Dichotomous test. This makes it more difficult to 
carry out. The test should be presented under high levels of illumination (> 500 
lux). Rather than measuring the overall hue discrimination ability, it is used to 
detect moderate and severe colour deficiencies (Figure 2-5). 
 
 
Figure 2-5:  Illustration of the Lanthony’s Desaturated Panel 15 test. 
 
2.3.2.2.3  Lanthony New Colour Test 
This test is intended to distinguish between mild, moderate and severe colour 
deficiency. It is formed of 70 Munsell samples, four series of 15 colours and 10 
grey caps. The observer is required to arrange the coloured caps in colour order 
and the grey caps in order of lightness scale. Results are plotted on a graph and 
an error score is then calculated. 
 
 59 
 
2.3.2.3  Nagel anomaloscope 
The Rayleigh match was first described by Rayleigh (1881) and developed into 
an instrument for assessing red / green colour vision by Nagel in the early 1900's.  
It was designed for clinical evaluation of colour deficiency. The observer is 
presented by circular bipartite field subtending 3° in Maxwellian view, the lower 
hemi-field is illuminated with yellow light source, the luminance of which can be 
varied and the upper hemi-field is formed of mixture of adjustable red and green 
lights.  
The test requires the observer to make colour matches by adjusting both the 
red-green ratio and the luminance of the yellow field. The observer is then 
required to determine whether adjustments in the luminance of the yellow field 
can or can’t produce exact matches to red-green ratios that are set by the 
examiner. The type of colour deficiency is determined from the patterns of 
variation in the red/green mixture range and the intensity of the yellow field 
needed to match this variable mixture (Birch, 2001) (Figure 2-6). 
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Figure 2-6: Illustration of the Nagel anomaloscope and the bipartite field. The 
upper hemi-field is formed from mixture of monochromatic red and 
monochromatic green and the lower hemi-field is illuminated with 
monochromatic yellow light source (adapted from Schiefer et al., 2007). 
 
The ratio of red and green is quantified; this ratio is between 0 for 
monochromatic green to 73 for monochromatic red. Subjects with normal 
colour vision will typically be able to make a Rayleigh match when the 
proportion of the two lights are nearly equal (i.e.; in the range of 35 - 40). In a 
protan subject, they will need to increase the proportion of red light in the 
mixture in order to make a match. So protans will be able to match range of 
mixtures between 40 and 73. A deutan subject will require greater proportion 
of green light achieving the mixture range between 0 and 40. 
The accuracy of diagnosis requires interpretation of the result by an experienced 
examiner to be able to interpret whether the subject has made a match or not 
based on their responses. In a study by Barbur et al., (2008) subjects with known 
genetic congenital colour deficiency still managed to make a Rayleigh match 
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within the normal range (Barbur et al., 2008). This means that the Nagel 
anomalscope is not as perfect instrument, as previously thought. 
 
2.3.2.4  Automated / computerized tests 
Some of these tests are based on the principals of the arrangements tests and 
others are based on colour contrast sensitivity. Examples of these tests include 
the Sussex Gratings Machine (SGM), the Chroma test and the Cambridge colour 
test. 
 
 
2.3.3  Electroretinography 
 
Several studies were conducted to investigate the neuroretinal changes using 
either full field or multifocal ERG. Those studies describe delayed or declined 
oscillatory potentials which are produced by the amacrine cells (Wachtmeister 
at al., 1978). Holopigian et al., (1997) investigated group of 12 diabetic patients 
with duration of diabetes more than 5 years. They detected delay in the a and b 
waves denoting changes in the photoreceptor cells. Similar results were shown 
by Fortune et al., (1999) they examined patients with 10-15 years duration of 
diabetes using multifocal ERG, they reported delay in the implicit time. 
 
2.3.4  Microperimetry 
 
It is used to measure retinal sensitivity. Several studies investigated the 
relationship between structural changed occurring within retinal layers in 
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diabetic patients and the effect that this would have on retinal sensitivity. As in 
recent study by Montesano et al., (2017), where they compared the retinal 
sensitivity to ganglion cell layer-inner plexiform layer thickness in 35 normal 
subjects and 26 diabetic subjects with no DR. They detected significant 
correlation between retinal sensitivity and the correspondent GCL-IPL thickness 
in diabetic subjects (0.022±0.006 dB/μm, p=0.0007) but not in healthy subjects 
(-0.002±0.006 dB/μm, p=0.77). 
 
In another recent study by Nerianuri et al., (2017) they detected reduction in 
retinal senstivity measured by microperimetry in 245 subjects with no DR. 
Where mean retinal sensitivity was 14.78 ± 3.17 dB in subjects with absent 
diabetic neuropathy (DN) compared to 13.56 ± 3.65 dB in subjects with DN. This 
indicates the presence of neuroretinal dysfunction even in the absence of DR 
and supports the theory that neuronal changes precede the onset of vascular 
changes. 
 
2.3.5  Contrast sensitivity 
 
Contrast sensitivity (CS) is known to be affected in diabetic patients even in 
absence of DR (Della Sala et. al., 1985) (Di Leo et al., 1992). It was demonstrated 
in recent study by safi et al., (2017) they compared CS in 46 diabetic subjects 
with no DR to 46 normal control subjects. They measured CS at four spatial 
frequencies (3, 6, 12, 18 cycles per degree) under moderate (500 lux) and dim 
(less than 2 lux) background light conditions. CS was impaired in diabetic 
subjects at an early stage, before any clinical signs of retinopathy were detected. 
Nerianuri et al., (2017) measured CS in 613 subjects with no DR, CS was 1.36 ± 
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0.17 log units in absence of DN compared to 1.25 ± 0.21 log units in subjects 
with DN. 
 
2.3.6  Aim of study 
This study was set up to investigate the pattern of RG and YB CV loss in diabetic 
patients. In particular, we wanted to investigate the advantages of using the CAD 
test to detect and quantify severity of CV loss in patients with diabetes. The 
correlation with other diabetes-related factors such as type, grade, control and 
duration will be examined. The ability of the CAD test to detect early loss of 
colour vision that precedes other functional changes will also be investigated.   
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 3 METHODS 
 
This chapter describes the criteria and recruitment process of the subjects, 
assessment of the grade of DR and the tests that were used for measuring 
chromatic sensitivity and retinal thickness as well as a list of other patient-
specific information that was collected such as duration and control of diabetes, 
HbA1C and previous medical and ophthalmic histories. 
 
3.1 SUBJECTS 
 
Subjects were recruited from the Ophthalmology outpatient department of 
King’s College Hospital NHS Foundation Trust, London. The study was approved 
by the Integrated Research Application System (IRAS) (Ref:11/NW/0753), King’s 
College Hospital Research and Ethics Committee as well as City, University of 
London Research and Ethics Committee. The study adhered to the principles of 
the declaration of Helsinki. Each subject was provided with an information sheet 
prior to their agreement to participate and was required to provide informed 
signed consent before taking part.  
Only subjects who met the inclusion criteria were recruited into the study. The 
inclusion criteria for the study required that all subjects: 
 Were aged 35 years or above, of either sex. Type II diabetes is more common 
after the age of 40-45 years and Type I is rare after that age (www.nhs.uk), 
so we set age 35 or above as an inclusion criteria to avoid a wide variation in 
age group between type I and Type II diabetics.  
 Were able to provide informed consent. 
 Had established diagnosis of Diabetes (Type I or II). 
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 Had no other ocular disease apart from DR. 
 Had normal CV (subjects with congenital CV loss as assessed by the CAD test 
were excluded from our analysis). 
 None of the subjects included in this study were taking medication known to 
affect CV, e.g. Digoxin (Lawrenson et al., 2002), ethambutol, chloroquine, 
hydroxychloroquine, phenytoin or sildenafil (Santaella and Fraunfelder, 
2007). 
The RG congenital colour deficiency affects about 8% of men and about 0.4% of 
women (Birch, 2001) and therefore we can expect at least 1 female and 5 males 
from our recruited subjects to have congenital RG deficiency. The reported 
average prevalence of colour blindness in the United Kingdom is 4.7% 
(www.nhs.uk). Initially subjects were asked about family history of CV loss and 
were considered to be normal if the answer was negative. However, after 
examining the results from the CAD test, we were able to detect 4 subjects with 
congenital CV loss, out of the 106 recruited (3.77%). Those are the subjects who 
exhibit RG losses whilst maintaining normal YB thresholds. Those subjects were 
excluded from the analysis.  
In addition, subjects were excluded from the study if: 
 Their best spectacle corrected visual acuity (BSCVA) was worse than 6/12 (0.3 
LogMAR). 
 They suffered from any other disease or had any other eye disease which 
could affect CV or mask the identification of the CAD test screen (e.g. multiple 
sclerosis and optic neuritis) (Russell et al., 1991). 
 Any ocular condition in the study eye that could affect the results of the test, 
such as dense cataract of the crystalline lens or intraocular pressure ≥ 21 
mmHg. 
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The density of cataract was graded using Lens Opacities Classification System III 
(LOCS III) (Chylack et al., 1993) (appendix C), any patient with NO3, NC3, C3 or 
P2 or more was excluded.  
 
The above inclusion / exclusion criteria were designed to enable the 
investigation of chromatic sensitivity threshold losses which are most likely to 
be caused by diabetes rather than any other, potentially confounding factors. 
Although the CAD test is least dependent on visual acuity, but usually poor visual 
acuity implies advanced retinal pathology with significant structural changes at 
the fovea. By recruiting subjects with 6/12 or better acuity, we ensure that CAD 
thresholds are not affected by other factors and that any changes in CV are likely 
to be the result of diabetes. 
 
Subjects were recruited from the routine retinal clinics at King’s College Hospital 
NHS Foundation Trust, this meant that assessment of presenting visual acuity 
was measured monocularly for distance only using Snellen’s chart starting with 
the right eye and followed by the left eye. This was carried out by qualified 
nurses. For purpose of analysis, the measured values were transformed to 
LogMAR units using a calculator obtained from 
http://www.myvisiontest.com/logmar.php. Following the measurement of 
presenting visual acuity, subjects had their pupils dilated by instilling 
Tropicamide 1% eye drops in both eyes. Pupil size does not affect colour 
thresholds (Barbur et al. 1997; Barbur and Rodriguez-Carmona, 2012), also the 
background luminance and stimulus size employed in the CAD test are set to 
allow for variation in pupil size and viewing distance (Barbur and Rodriguez-
Carmona, 2015) giving confidence that any variations in CV were not a result of 
variation in pupil size. 
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3.2 OPHTHALMOLOGICAL EXAMINATION 
Full clinical ophthalmic examination was performed and this included taking 
medical and ophthalmic history together with other patient-specific 
information such as duration, control of diabetes and HbA1c. Subjects were 
then examined using a slit lamp for biomicroscope, followed by dilated fundus 
examination using non-contact 90D and digital wide field Volk® lenses. 
Intraocular pressure (IOP) was measured using Goldmann’s applanation 
tonometry. At this stage, subjects were asked to join the study and those who 
were willing to take part, were given an information leaflet about the study 
and invited to sign the consent form (appendix A and B). 110 out of 115 
subjects agreed to take part in our study (95.6% acceptance).  
 
 
3.3 OPHTHALMIC INVESTIGATIONS AND IMAGING 
All subjects had OCT scans using the standard protocol on the Heidelberg 
Spectralis SD-OCT (Heidelberg engineering GmbH, Heidelberg, Germany) (see 
section 3.3.2 for details of procedure). All scans were performed by two 
experienced medical photographers.  
Subjects who were referred as new patients from the Diabetic Screening Service 
(DSS) had their fundus photos taken at screening and these were available for 
the study.  Other subjects who were seen in clinics as follow-ups had their 
fundus photos taken specifically for this study by an experienced medical 
photographer. Photos were saved for future referencing and grading purposes.  
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This was followed by monocular measurements of chromatic sensitivity, using 
the CAD test (Barbur et al, 1994; Barbur and Connolly, 2011). 
 
DR was graded according to ETDRS severity scale (discussed previously in section 
2.2) as: no retinopathy, mild, moderate, severe DR, presence/absence of MO, 
and active or treated PDR.  
 
3.3.1 Chromatic sensitivity 
 
The standard CAD test measures chromatic sensitivity along 16 hue directions in 
the Commission Internationale d’Eclairage (CIE) 1931 - (x,y) chromaticity chart. 
The directions selected are grouped together to assess red-green and yellow-
blue chromatic sensitivity.  
The stimulus is generated with 30 bit resolution in the centre of a large uniform 
background field on a visual display (La CIE Electron Blue, 20” CRT monitor). The 
stimulus consists of a square array of 15 x 15 achromatic checks, subtending a 
horizontal visual angle of approximately 3.3° x 3.3° at a viewing distance of 1.4m. 
The background chromaticity is set as the MacAdam ‘white’ in the 1931 CIE – 
(x,y) chromaticity coordinates: x=0.305,  y=0.323. The luminance of each checker 
scintillates every 40 to 80 ms, with equal probability, within a range defined as 
a percentage of background luminance; the standard CAD recipe employs 
dynamic noise amplitude of ± 45%. The variation of the checks is such that the 
average check luminance over time and the average spatial luminance of the 
stimulus remain unchanged and equal to that of the background, thus providing 
a steady state of light adaptation independently of any chromatic displacement. 
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This random luminance modulation is applied spatially and temporally, creating 
achromatic dynamic luminance contrast (LC) noise that masks the detection of 
luminance contrast signals and isolates the use of chromatic signals (Barbur and 
Ruddock, 1980; Barbur et al., 1981; Barbur et al., 1994; Rodriguez-Carmona et 
al., 2005). 
There is a smaller, colour-defined, square outline (comprising 5 x 5 checks and 
subtending a visual angle  ̴ 0.8° at a viewing distance of 1.4 m) buried in the 
larger array of LC checks. The test stimulus moves at a speed of   ̴ 4°/s along the 
diagonals of the larger square defined by LC noise (Figure 3-1). An efficient, four-
alternative, forced-choice procedure is used to measure the subject’s chromatic 
displacement thresholds, the subject’s task is to press one of four buttons 
arranged at the corners of a square on a wireless response control, following 
each stimulus presentation to indicate the direction of motion of the colour 
defined stimulus. Each presentation is followed by a brief audio cue to prompt 
the subject to make a response. The correct direction has to be reported twice 
in succession before the colour signal of the stimulus is decreased, according to 
the interleaved staircase procedure making the chance probability of a correct 
response 1 in 16 (Barbur, 2004). 
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Figure 3-1: The appearance of the CAD test moving coloured stimuli during the 
test together with the numeric keypad used to record the subject’s responses. 
The colours shown correspond to the RG and YB isolating axes.  
 
The CAD test algorithm averages the thresholds measured for some of the hue  
directions investigated to compute the mean RG and YB thresholds. Subjects 
with refractive errors wore their appropriate refractive correction for the 
corresponding distance.  
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Figure 3-2: CAD test result for typical, normal trichromat plotted in the CIE 
1931 (x,y) chromaticity chart. The black cross at the centre of the diagram plots 
the chromaticity of the white background i.e., 0.305, 0.323. Grey shaded area 
shows the range of variation expected in normal CV at the corresponding age 
(see Fig. 3.3). The red and blue arrows represent 1 CAD unit for RG and YB, 
respectively. The normal, upper threshold limits have been measured as a 
function age and are used by the CAD test to decide whether the subject’s RG 
and YB thresholds are within the normal range (Barbur & Rodriguez-Carmona, 
2015). 
 
 
All subjects were positioned 1.4 m away from the visual display with the eye 
horizontally in line with the centre of the monitor, the test was carried out 
monocularly in the eye with the best VA. The ‘definitive’ CAD test takes ~ 8 
minutes to assess RG and ~ 4 minutes to assess YB thresholds.   The ‘learning 
mode’ required 100% correct responses to ensure that the subject understood 
the testing procedure and the use of the numeric keypad (see Fig. 3.1). 
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The initial validation of the CAD test and the statistical limits for the normal CAD 
observer is based on RG and YB thresholds measured in 330 young, healthy 
subjects with normal trichromatic colour vision (Civil Aviation Authority, 2009). 
  
Figure 3-2 shows the CAD template plot for a normal trichomat , where the grey 
shaded area shows the range of variation expected in normal CV, the innermost 
and outermost ellipses corresponding to 2.5% and 97.5% confidence limits for 
normal population, respectively (Rodriguez-Carmona et al., 2005). The dotted 
black ellipse represents median value for the standard normal trichromatic; this 
is expressed in ‘standard normal units’ (SNU) which is taken as 1 SNU. 
 
 
3.3.1.1 Age related changes in colour vision 
Many changes that take place during the aging process will affect CV, although 
this change is gradual and can often go unnoticed for several years.  The first of 
these changes takes place in the pre-receptoral filters of the eye, the most 
important of which, is the crystalline lens. The lens acts as a filter for the 
transmittance of short wavelength light, preventing wavelength shorter than 
300 nm from reaching the retina. The lens has high optical density (OD) that 
decreases rapidly above 450 nm allowing the transmission of incident light for 
wavelengths longer than 560 nm (Norren and Vos, 1974). Aging and increased 
absorption of short wavelength light cause the yellowish appearance of the lens 
(Pokorny et al., 1987; Weale, 1988). This reduction in transmission affects the 
retinal illuminance and affects mainly short wavelength light. This contributes 
to the more rapid loss of YB chromatic sensitivity seen with aging (Barbur and 
Rodriguez-Carmona, 2015). 
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The macular pigment optical density (MPOD) also affects the absorption of light. 
It is yellow in appearance and absorbs light in the blue range of visible spectrum 
with peak absorption at   ̴ 460 nm (Bone et al., 1992). Age related changes at the 
macula have been identified as an underlying cause of reduced chromatic 
sensitivity (O’Neill-Biba et al., 2010). 
The linear loss of retinal ganglion cell (RGC) axons and cell bodies is another 
important factor contributing for increased RG and YB thresholds observed in 
normal aging. There is about 40% linear reduction in RGC axons during the life 
span (Jonas et al., 1992; Neufeld and Gachie, 2003; Calkins, 2013). The rod 
photoreceptor density reduces but the number of cones remains relatively 
constant in normal ageing (Curcio et al., 1993). 
Barbur and Rodriguez-Carmona (2015), studied the effect normal aging has on 
RG and YB thresholds, as measured with the CAD test. They found that the 
optimum age for best colour thresholds was around   ̴ 20 years of age, this was 
followed by gradual and linear increase of   ̴1% per year for RG and   ̴1.6% for YB 
thresholds over the remaining life span (Figure 3-3). The mean monocular 
thresholds as a function of age are given by the following equation:  
RGmon = 0.901 + 0.0156*age +4.351*exp(-0.19*age) and  
YBmon = 0.306 + 0.0283*age +3.889*exp(-0.1136*age). 
Then to evaluate the upper normal limit (±2.5) one must add 0.993 to RG and 
1.027 to YB. 
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Figure 3-3: Normal trichomats RG and YB thresholds for age. A graph showing 
the RG and YB thresholds as a function of age for normal trichomats subjects 
(Barbur and Rodriguez-Carmona, 2015). 
 
 
3.3.2 Optical coherence tomography 
OCT has established itself as valuable and some might argue essential method 
in the evaluation and management of retinal diseases in general and macular 
diseases in particular (Drexler and Fujimoto, 2008). It has allowed virtual 
visualization of the human retina at high resolution and given a new aspect in 
the interpretation of clinical findings. Since it was introduced in the late 1990s, 
it has evolved hugely reaching a resolution which allows visualisation of retinal 
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details down to 10µm. This has helped in better understanding of pathologies of 
various retinal diseases and has greatly improved clinical diagnosis and 
increased current knowledge of DR, in particular with detection and 
qualification of MO and modified current management approaches.  
 
OCT scans were carried out using the standard protocol on the Heidelberg 
Spectralis SD-OCT. All scans were performed by two experienced medical 
photographers. The subject was asked to fixate on a stimulus, a cross green 
segments arranged like a star. During the examination, the patient was able to 
see the stimulus and a red scanning segment moving along it at the same time. 
During the scan the operator is able to visualise an external view of the eye, real 
time fundus image and the OCT images of the macula, after the capture of the 
scan qualitative information is shown on the review screen and any scan with 
quality signal ≤7 is disregarded. The Spectralis OCT camera uses an internal 
fixation source that tracks the subject’s fovea and an infrared camera through 
which the stability of fixation can be monitored by the operator. The cross-
sectional images are then analysed using incorporated software that is capable 
of mapping the strongest two edges in each tomogram that present the 
vitreoretinal interface and the basement membrane of the retinal pigment 
epithelial (RPE) – Bruch’s membrane; respectively. Retinal thickness (RT) 
measurements are generated automatically and were obtained in 9 subfields 
(Figure 3-4 and 3-5) and described in the ETDRS. These subfields are arranged in 
inner, intermediate and outer rings with radii of 1mm, 2.22mm and 3.45mm 
respectively. The average of all points within the inner circle is defined as central 
sub-field thickness (CSF). 
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Figure 3-4: The standard 9 ETDRS subfields (Right) with their corresponding 
overall mean RT measurements (Left). CSF= central subfield; IIM= inferior 
inner macula; IOM= inferior outer macula; NIM= nasal inner macula; NOM= 
nasal outer macula; SIM= superior inner macula; SOM= superior outer macula; 
TIM= temporal inner macula; TOM= temporal outer macula. 
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Figure 3-5: The appearance of Heidelberg Spectralis SD-OCT, scan showing 
normal right eye with retinal thickness measurements obtained in the 9 ETDRS 
subfields, including central subfield (CSF).  
 
3.4 STATISTICAL ANALYSIS 
The data were analysed using Microsoft Excel (MS Excel 2013, Seattle, WA, USA) 
and SPSS programs (SPSS V.22.0, SPSS, Chicago, IL, USA). Analysis was performed 
using t-tests to calculate p values and data were assumed significant if p<0.05. 
Categorical variables were examined using Pearson’s r correlation.  
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4   RESULTS  
4.1 SUBJECTS  
A total of 106 subjects were recruited according to the inclusion criteria outlined 
in section 3.1. All subjects were assessed for RG and YB CV using the CAD test, 
as described in section 3.4. Only 102 subjects were included in the analysis as 
the CAD test results identified 4 subjects with congenital RG colour deficiency. 
This is usually the case when subjects exhibit RG losses whilst maintaining 
normal YB thresholds.   
8% and 0.4% of healthy males and females, respectively have abnormal cone 
pigments and exhibit RG colour deficiency (Birch 2001) with the average 
prevalence of colour blindness in the United Kingdom estimated to be 4.7% 
(www.nhs.uk) which matches our findings as 4 out of 106 subjects (3.77%) had 
congenital colour deficiency.  
 
4.1.1 Acquired causes for colour vision loss: 
4.1.1.1 Lens opacity 
9 out of 102 subjects (9%) were pseudophakic, the remaining had variable 
degrees of lens opacification. The density of lens opacity was graded using Lens 
Opacities Classification System III (LOCS III) (Chylack et al., 1993) (Appendix C). 
This system uses a photographic set of images to illustrate different grades of 
nuclear, cortical and posterior subcapsular lens opacities. The grades range from 
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1 to 4, nuclear opalescence grade of NO1–NO2 or a nuclear colour grade of NC1–
NC2 (Table 4-1). 
Subjects included in our study were graded as follows: 
Grade No. of subjects 
N01 77 
N01C1 10 
N01C2 2 
N02 1 
N02C2 2 
P1 1 
Table 4-1: Grades of lens opacities in subjects recruited in the study. 
The increase in lens opacity causes a decrease in the transmittance of short 
wavelength light which in turn leads to reduction in retinal illuminance. This 
effect may contribute to the more rapid loss of YB chromatic sensitivity seen 
with aging (Barbur and Rodriguez-Carmona, 2015). It was therefore important 
to consider this, as this could potentially be a confounding factor in our analysis. 
We therefore analysed our results after matching for age groups and considering 
the age related upper threshold limits to enable us to separate the more gradual 
RG and YB losses which are attributable to normal aging from the diabetes 
induced changes. 18 subjects had RG thresholds below the corresponding, age-
matched, upper normal limit, but only 4 of the subjects had YB thresholds within 
the normal range. All other subjects had RG and YB thresholds higher than 
expected for their corresponding age. This loss was higher than the normal 
gradual loss seen with aging and most likely losses must be caused by other 
factors such as the diabetes induced changes.  
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4.1.1.2 The effect of age on chromatic sensitivity 
We compared the RG and YB thresholds results to the age matched controls. 
Only 19% of the diabetic subjects (n=19) had colour thresholds within the 
normal age limits (Figure 4-1). The age matched values were obtained from 
previously available data published by Barbur et al., 2015, using data from 443 
normal eyes for RG and 456 normal eyes for YB CV. The results provided mean 
monocular RG and YB thresholds and the corresponding ±2.5σ limits as a 
function of age. 
 
Diabetics with either RG or YB monocular thresholds above normal limits 
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Figure 4-1: RG and YB thresholds measured in the diabetes group plotted as a 
function of age together with the corresponding data for normal, healthy 
trichromats (normative data based on 443 and 456 eyes for RG and YB, 
respectively which were filtered for congenital and acquired colour 
deficiencies). The results show that 82% and 96% subjects had RG and YB 
thresholds, above the corresponding normal upper age limits, respectively. 
 
                                    
4.1.1.3 The effect of drugs on chromatic sensitivity: 
As described in the inclusion and exclusion criteria in section 3.1, to our 
knowledge none of the subjects recruited in this study were taking medication 
known to affect CV. 
 
4.2 ANALYSIS 
The analysis included 102 subjects, 61 (60%) males and 41 (40%) females. 
Subjects were divided in 3 groups according to the severity of their DR. The 3 
groups were; Group 1: No or mild NPDR, group 2: Moderate to severe NPDR and 
group 3: Active or treated PDR. 
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4.2.1 Group (1): No or mild NPDR 
4.2.1.1 Descriptive data 
This group included 67 subjects. The subjects demographic and baseline 
characteristics are shown in table 4-2. 
Mean age (SD), years                                                                   56±12.14 
Range, years                                                                                  35-84 
Gender, n (%) 
    Male, n (%)        40 (60) 
 Female, n (%)                                                    27 (40) 
Race, n (%) 
    Afro-Caribbean                                                                   40 (60) 
    Asian           5 (7) 
 Caucasian                                                                              22 (33) 
Smokers, n (%)         1 (1.5) 
Mean HbA1C, n* (SD)       8.14±1.55 
 ≤8%, n (%)         25 (57) 
 >8%, n (%)         19 (43) 
Type of diabetes, n (%) 
           Type I                                                                                            6 (9) 
           Type II                                                                                           61 (91) 
Control of diabetes, n** (%) 
          Diet control                                                                                 1 (1.5) 
          Metformin                                                                                   36 (54) 
          Insulin                                                                                           17 (25) 
          Insulin + Metformin                                                                   7 (10) 
Mean duration of diabetes (SD), years                                             15.51±10.65 
Range, years                                                                                          1.5-40 
Hypertensives on treatment, n (%)               32 (48) 
Previous macular laser, n (%)                2 (3) 
Vision in LogMAR,                  
 ≤0.00, n (%)                  61(91) 
 >0.00, n (%)                 6 (9) 
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Abbreviations: HbA1C, glycosylated haemoglobin; 
*n =44, as data is missing for 23 patients 
** n=61, as data is missing for 23 patients  
Table 4-2: Subjects demographic and baseline characteristics for group 1 (no 
or mild NPDR). 
 
4.2.1.2 Change in RG and YB thresholds in group 1 
17 (25%) subjects in this group had RG and YB thresholds within the normal 
limits, the remaining 50 (75%) subjects showed varying degrees of chromatic 
sensitivity loss. The mean RG and YB thresholds for the group as a whole were 
3.69±3.95 and 4.92±4.21 SNU, respectively. The 50 subjects with RG and YB 
thresholds outside the normal limits had RG and YB threshold of 4.42±4.37 and 
5.81±4.54 SNU, respectively. There were 43 subjects with RG thresholds <6, 
their mean thresholds were 3.20±1.33. Similarly, 34 subjects had YB thresholds 
<6, (3.26±1.03). 
Most subjects (n=61) had BCVA 0.00 LogMAR or better except for 3 subjects who 
had LogMAR VAs of 0.08, 0.12 and 0.34. 2 out of the 3 subjects had undergone 
previous macular grid laser treatment. 
In this group the ±2σ central subfield thickness (CSF) as measured on OCT was 
289±72 µm (range 214 to 362 µm). 
 
4.2.2 Group (2): Moderate to severe NPDR 
4.2.2.1 Descriptive data 
This group included 22 subjects. The subjects demographic and baseline 
characteristics are shown in table 4-3. 
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Mean age (SD), years                                                                   55±11.98 
Range, years                                                                                  35-76 
Gender, n (%) 
    Male, n (%)        13 (59) 
 Female, n (%)                                                    9 (41) 
Race, n (%) 
    Afro-Caribbean                                                                   9 (41) 
    Asian           0 (0) 
 Caucasian                                                                              13 (59) 
Smokers, n (%)         3 (14) 
Mean HbA1C, n* (SD)       7.66±0.92 
 ≤8%, n (%)         9 (60) 
 >8%, n (%)         6 (40) 
Type of diabetes, n (%) 
           Type I                                                                                            6 (27) 
           Type II                                                                                          16 (73) 
Control of diabetes, n (%) 
          Diet control                                                                                 1 (0.5) 
          Metformin                                                                                   7 (32) 
          Insulin                                                                                           8 (36) 
          Insulin + Metformin                                                                   6 (27) 
Mean duration of diabetes (SD), years                                             20.77±11.18 
Range, years                                                                                          1-43 
Hypertensives on treatment, n (%)               13 (59) 
Previous macular laser, n (%)                3 (14) 
Vision in LogMAR,                  
 ≤0.00, n (%)                  17 (77) 
 >0.00, n (%)                 5 (23) 
 
Abbreviations: HbA1C, glycosylated haemoglobin; 
*n =15, as data is missing for 7 patients 
Table 4-3: Subjects demographic and baseline characteristics for group 2 
(moderate and severe NPDR). 
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4.2.2.2 Change in RG and YB thresholds in group 2 
Most subjects (n=20) in this group showed RG and YB losses above the normal 
age limits. The mean RG and YB thresholds for the group as a whole were 
4.77±4.16 and 6.72±5.17 SNU, respectively. After excluding the 2 subjects with 
RG threshold within the normal age limit, the mean RG was 5.09±4.23 and YB 
was 7.10±5.27 SNU. 
Most subjects (n=17) had BCVA 0.00 LogMAR or better except for 1 subject who 
had BCVA of 0.08 LogMAR and 4 other subjects who had BCVA of 0.18 LogMAR. 
In this group the ±2σ CST as measured on OCT was 272±36 µm (range 215 to 
344 µm). 
 
4.2.3 Group (3): Active or treated PDR 
4.2.3.1 Descriptive data 
This group included 13 subjects. The subjects demographic and baseline 
characteristics are shown in table 4-4. 
Mean age (SD), years                                                                   54±12.31 
Range, years                                                                                  37-68 
Gender, n (%) 
    Male, n (%)        8 (62) 
 Female, n (%)                                                    5 (38) 
Race, n (%) 
    Afro-Caribbean                                                                   4 (31) 
    Asian           0 (0) 
 Caucasian                                                                              9 (69) 
Smokers, n (%)         2 (15) 
Mean HbA1C, n* (SD)       8.02±1.01 
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 ≤8%, n (%)         4 (50) 
 >8%, n (%)         4 (50) 
Type of diabetes, n (%) 
           Type I                                                                                            7 (54) 
           Type II                                                                                           6 (46) 
Control of diabetes, n (%) 
          Diet control                                                                                 0 (0) 
          Metformin                                                                                   2 (15) 
          Insulin                                                                                           8 (66) 
          Insulin + Metformin                                                                   3 (23) 
Mean duration of diabetes (SD), years                                             20.5±14.85 
Range, years                                                                                          2-56 
Hypertensives on treatment, n (%)               9 (69) 
Previous macular laser, n (%)                6 (46) 
Previous PRP laser, n (%)                                                                    9 (69) 
Vision in LogMAR,                  
 ≤0.00, n (%)                  7 (54) 
 >0.00, n (%)                 6 (46) 
 
Abbreviations: HbA1C, glycosylated haemoglobin; PRP. Pan retinal photocoagulation 
*n =8, as data are missing for 5 patients 
Table 4-4: Subjects demographic and baseline characteristics for group 3 
(Active or treated PDR). 
 
4.2.3.2 Change in RG and YB thresholds in group 3 
All subjects (n=13) showed RG and YB losses above the normal age limits. The 
mean RG and YB thresholds were 9.70±9.05 and 11.45±6.40 SNU, respectively 
(table 4-5). 
7 subjects had BCVA 0.00 LogMAR or better, 2 subjects had BCVA 0.04 LogMAR 
and remaining 4 subjects had BCVA ranging from 0.10-0.30 LogMAR. 
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In this group the ±2σ CST as measured on OCT was 351±105 µm (range 232 to 
629 µm). 
Group number Number of 
patients 
RG threshold YB threshold 
Group 1 50 4.42 ± 4.37 5.81 ± 4.54 
Group 2 20 5.09 ± 4.23 7.10 ± 5.27 
Group 3 13 9.70 ± 9.05 11.45 ± 6.40 
Table 4-5: Showing the RG and YB thresholds for subjects within the 3 groups 
who had thresholds outside the normal limits. 
 
4.3 CHROMATIC SENSITIVITY AND DIABETES 
4.3.1 Effect of grade of diabetic retinopathy on chromatic sensitivity 
 
The measured RG and YB thresholds for the subjects that showed CV loss were 
variable, with some exhibiting RG losses greater than YB and others showing YB 
losses greater than RG. 
The RG and YB losses were detected in the subjects irrespective of the presence 
or absence of DR. As seen with group 1, RG and YB losses were detected in 
subjects who had no or mild evidence of DR.  
The results also show that RG and YB thresholds losses increase with the severity 
of DR as illustrated in figure 4-2. When comparing the RG thresholds between 
the three groups using analysis of variance (ANOVA), F-value= 8.11, while F crit. 
= 3.08 (p<0.05). As for the YB thresholds, F-value=10.49, F crit. = 3.08, but this 
was not significant. These results suggest that there is a greater loss of chromatic 
sensitivity in patients with more severe DR.  
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1=  No or mild NPDR 
2=  Moderate to severe NPDR 
3=  Treated or active PDR 
 
Figure 4-2: RG and YB thresholds in three groups. Group 1: No or mild NPDR, 
group 2: Moderate to severe NPDR and group 3: Active or treated PDR. In 
group 1, RG and YB was 3.69±3.95 and 4.92±4.21, group 2 4.77±4.16 and 
6.72±5.17 and group 3 was 9.70±9.05 and 11.45±6.40. 
 
4.3.2 Effect of duration of diabetes on chromatic sensitivity 
The mean±2σ of duration of diabetes in our subjects was 15.51±10.86 years with 
a range of 1-56 years. We examined the data to see if the duration of diabetes 
would show an effect on the RG and YB thresholds. No correlation was observed 
between RG and YB thresholds loss and the duration of diabetes with r2= 0.0 and 
r2= 0.01 respectively (Figure 4-3). 
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Figure 4-3: Effect of duration of diabetes on measured RG and YB thresholds. 
It was measured in 102 patients who had diabetes for a duration that ranged 
between 1-56 years, mean±2σ was 15.51±10.86 years. 
 
4.3.3 Effect of control of diabetes on chromatic sensitivity 
The control of diabetes included measurement of HbA1C levels.  The mean±2σ 
was 8.13±1.56 %. This parameter did not correlate with losses of either RG or YB 
thresholds with r2=0.02 and r2=0.0 respectively. Another aspect of diabetes 
control is treatment; 47 (46%) subjects were using insulin alone or a 
combination of insulin and metformin, 45 (44%) subjects were using metformin 
alone and 2 (2%) subjects were only on diet control. Those two subjects were 
excluded from the analysis as it was a too small sample to assess any conclusive 
effect of diet control on the degree of CV loss. These data were not available for 
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8 (8%) subjects. Comparing the two groups, in the group that was controlled by 
either insulin or a combination of insulin and metformin the mean±2σ RG 
threshold was 5.00±5.65 SNU and YB threshold 6.49±5.11 SNU. The other group 
which had subjects controlled by metformin alone, the mean±2σ RG threshold 
was 4.91±5.19 SNU and YB threshold 6.41±5.48 SNU respectively (Figure 4-4). 
The mean of control of diabetes, whether it is insulin or metformin or both 
together didn’t seem to have an effect on the chromatic sensitivity levels 
(p=0.93 and 0.97). 
 
 
Figure 4-4: Effect of glycaemic control on measured RG and YB thresholds. 
HbA1C was measured in 67 subjects across the three different groups with 
mean±2σ 8.13±1.56 %. The control did not correlate with losses of either RG 
or YB thresholds. 
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4.3.4 Effect of Type of diabetes on chromatic sensitivity 
20 subjects (20%) were type 1 diabetes with mean±2σ RG threshold 4.48±4.94 
SNU and YB threshold 6.02±5.08 SNU. The other 82 subjects (80%) were type 2, 
their RG and YB thresholds were 4.70±5.25 and 6.14±5.17 SNU, respectively 
(Figure 4-5).  
No correlation was found between the type of diabetes and the severity of loss 
in RG and YB thresholds with r2=0.0 and r2= 0.0 respectively.  
 
  
Figure 4-5: Effect of type of diabetes on chromatic sensitivity. The severity of 
colour loss was nearly equal in both types of diabetes. 
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4.3.5 Correlation between central subfield thickness and chromatic sensitivity 
 
The mean±2σ CST was 282±52.4. A low correlation was found between RG and 
YB thresholds and the retinal thickness with r2= 0.15 and r2= 0.20 respectively 
(Figure 4-6). 
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Figure 4-6: Correlation between measured RG and YB colour thresholds and 
CST as measured in 102 subjects (r2=0.15 and r2=0.20 respectively). 
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4.4 VISUAL ACUITY 
In total, 85 subjects (83%) had BCVA 0.00 LogMAR or better (Figure 4-7). This 
meant that VA was not one of the variables examined in this study.  
 
 
Figure 4-7: VA plotted as a function of RG and YB CAD thresholds. 
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5 Acuity and colour vision changes post intravitreal 
Dexamethasone implant injection in patients with Diabetic 
Macular Oedema 
 
5.1 INTRODUCTION 
This chapter describes one of the main complications of DR which is DMO and 
its most recent modality of treatment which is injection of intravitreal steroid 
implant that has the ability to reduce the oedema as seen on OCT. We will 
investigate the pattern of CV changes in such patients prior to and post injection. 
 
DMO affects 20% of patients with DR (Yau et al., 2012) and can cause vision loss 
independent of the grade of retinopathy. 
 
DMO results from the breakdown of blood retinal barriers and accumulation of 
extracellular fluid within the inner and outer retinal layers creating diffuse 
thickening or cystoid spaces that can often extend to affect the whole retinal 
thickness. Such changes cause displacement in the retinal neuronal components 
with subsequent temporary or permanent visual loss (Pelosini et al., 2011). 
 
Inflammation is an important factor in the breakdown of the blood–retinal 
barrier with expression of prostaglandins, leukotrienes and VEGF (Bhagat et al., 
2009). As a result, steroids can play a vital role in decreasing intracellular and 
extracellular oedema through inhibition of these factors by suppression of 
macrophage activity, vasoconstrictive effect, and reduction of lymphokine 
production (Abe et al., 1999). 
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The standard care for DMO has evolved over several years and relies mostly on 
the control of the systemic condition: diabetes, blood pressure and lipid 
management. Macular laser photocoagulation was the mainstay of treatment 
for over 30 years. Direct intervention with focal or grid argon laser 
photocoagulation to treat areas of retinal thickening led to stabilization of vision 
(ETDRS report 1, 1985). 
 
More recently anti-VEGF has been introduced for use in the treatment of DMO. 
In 2012, Ranibizumab became the first medical agent licenced for the treatment 
of the condition. Findings from two phase III randomised trials (i.e., the RISE and 
RIDE studies) (Nguyen et al., 2012) show that monthly injections of anti-VEGF 
Ranibizumab in MO patients lead to a two to three-fold increase in the 
percentage of patients who gained ≥15 letters in BCVA from baseline at 24 
months compared with the sham treatment group. 
 
Steroids can also be useful in the treatment of DMO by blocking the production 
of VEGF and other inflammatory mediators. Several randomised clinical trials 
have reported on the use of steroids such as triamcinolone acetonide in the 
treatment of DMO with improvement in visual acuity and reduction of central 
retinal thickness (CRT) (Jonas et al., 2003) (DRCR network, 2008) (Gillies et al., 
2009). The use of steroids is, however, associated with raised IOP in up to 50% 
and cataract formation in 40% of the injected eyes (Lowenstein et al., 2006). 
Similar to ranibizumab the effect is short-lived and patients require frequent 
injections with higher cumulative risks of side effects adding more constraints 
on clinical resources. 
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Sustained release corticosteroids have been developed with the aim of offering 
longer lasting effects that reduce the need for frequent intravitreal injections. 
The dexamethasone intravitreal implant - Ozurdex (Allergan Inc., Irvine, CA, 
USA) is a sustained-release biodegradable implant made of polyacticglycolic acid 
matrix, containing dexamethasone that is injected into the vitreous through the 
pars plana using a customized applicator. It releases 700mg dexamethasone 
slowly into the posterior segment. This treatment demonstrated efficacy in the 
treatment of chronic DMO and DMO which is resistant to anti-VEGF treatment 
(Kuppermann et al., 2007; Boyer et al., 2014) 
 
The OCTOME study was conducted in the Laser and Retinal Research Unit of 
King’s College Hospital, London. This was a single centre, exploratory phase III, 
prospective, open-label clinical study. The study was designed to evaluate the 
morphological and functional changes following treatment with Ozurdex in 
patients with MO secondary to DR and vein occlusion. In total, 30 patients with 
persistent MO were recruited: 24 with DMO, 5 with MO secondary to branch 
retinal vein occlusion, and 1 with Irvine-Gass syndrome.  
 
OCTOME report 1 confirmed that the therapeutic effect of Ozurdex lasts up to 
36 weeks in terms of improvement of visual function and macular thickness in 
patients with MO. It also concluded that if re-treatment is needed, re-injection 
of Ozurdex at 20 weeks is appropriate timing in terms of balancing effectiveness 
with least side-effects (Mathew et al., 2014). 
 
Although measurement of retinal thickness by OCT scan is a useful tool to 
monitor the response to treatment, it cannot substitute the measurement of 
visual acuity and both OCT and visual acuity have a place in the monitoring of 
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diabetic changes. It is however well established that visual acuity does not 
always correlate well with clinical severity of MO (Browning et al., 2007). Other 
visual functions such as functional contrast sensitivity, CV and rapid flicker 
sensitivity may provide a better understanding of the effect of Ozurdex on MO. 
In this study we measured and compared changes in RG and YB colour 
thresholds with the corresponding changes in visual acuity and CST to quantify 
the effects of Ozurdex treatment on other aspects of vision. The patients 
investigated represent only a small subgroup of the patients recruited for the 
larger OCTOME study (Mathew et al., 2014). 
 
Our specific aim was to measure and compare changes in RG and YB thresholds 
using the CAD test (Barbur and Connolly, 2011) (Figures 3-1 and 3-2) in patients 
with DMO pre- and post-Ozurdex (Dexamethasone implant) intravitreal 
injection. The study assessed the severity of RG and YB colour loss before 
treatment and established whether treatment with Ozurdex led to 
improvement (or at least stabilisation) of chromatic sensitivity. It is also of 
interest to establish whether changes in chromatic sensitivity can be used to 
evaluate the efficacy of Ozurdex treatment of DMO. 
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5.2 METHODS 
Subjects were recruited from the Ophthalmology outpatient department of 
King’s College Hospital NHS Foundation Trust, London. The study was approved 
by the Integrated Research Application System (IRAS) (Ref: 11/NW/0753), King’s 
College Hospital Research and Ethics Committee as well as by the Research and 
Ethics Committee of City, University of London).  The OCTOME study is an 
interventional, prospective, exploratory study (ISRCTN - 66216819). It was 
conducted following approval from the Institutional Review Board Ethics 
Committee (11/H0718/6; NRES committee London Central) and all participants 
gave written informed consent. The study adhered to the principles of the 
Declaration of Helsinki. 
 
5.2.1 SUBJECTS 
This study examined 14 diabetic patients with DMO. The participants represent 
a subset recruited from the 24 diabetic patients examined in the OCTOME study. 
The remaining 10 diabetic patients, not included in this study, had either age 
related decline in cognitive ability or very poor visual acuity. As a result they 
were unable to complete the one minute learning stage which does not rely on 
the use of CV. The ten patients excluded from the study failed to achieve the 
100% correct responses required in the learning task which precedes the full 
CAD test. During the learning task, the CAD stimulus (Figure 3-1 and 3-2) is 
defined by both colour and luminance contrast and is always seen by both 
normal trichomats and colour deficients. 100% performance in the learning task 
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is needed to ensure that the patients understand the requirements of the visual 
task and can use the keypad response buttons without error. 
 
The OCTOME study had thirty patients in total with MO secondary to different 
retinal vascular disorders such as DR, branch retinal vein occlusion or following 
cataract surgery. The exclusion criteria employed in this investigation mirrored 
the OCTOME study. All participants had to meet the criteria listed below: 
 The best corrected visual acuity (BCVA) in the study eye had to be in the 
range 37 and 68 ETDRS Letters, this level of performance is equal to 1.26 
and 0.64 LogMAR acuity, respectively. 
 Patients were excluded if they had any other eye disease which could 
mask or contribute to MO, or any ocular condition in the study eye that 
would prevent a 15-letter improvement in visual acuity (e.g., severe 
macular ischemia, extensive macular laser scarring, or atrophy).  
 Patients were also excluded if they had advanced glaucoma that was not 
controlled adequately by drugs alone, or a history of IOP elevation in 
response to steroid treatment in either eye that resulted in ≥10mmHg 
increase from baseline with an absolute IOP ≥25mmHg, or required 
therapy with three or more anti-glaucoma medications. 
 Patients were excluded if they had any systemic conditions that precluded 
trial entry such as known uncontrolled systemic disease or current 
immunosuppressive disease, initiation of medical therapy for diabetes, or 
a change from oral hypoglycaemic agents to insulin therapy within 4 
months before the screening visit and renal failure requiring 
haemodialysis or peritoneal dialysis within 6 months before screening 
visit. 
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5.2.2 OPHTHALMIC ASSESSMENTS 
As part of OCTOME study protocol, all patients were examined every 4 weeks. 
On every visit patients underwent baseline examination of monocular best 
corrected visual acuity (BCVA) which was measured using standard ETDRS 
protocol at 4m distance with a modified ETDRS distance chart. Visual acuity was 
scored as the total number of ETDRS letters read correctly. This was followed by 
dilated fundoscopy that was performed using non-contact 90D and digital wide 
field Volk® lenses, IOP was measured using Goldmann’s applanation tonometry, 
and OCT scans were obtained on Spectralis SD-OCT (Heidelberg engineering 
GmbH, Heidelberg, Germany). Other visual function tests- monocular as well- 
were performed at baseline and repeated at week 24. These included contrast 
sensitivity with the Pelli-Robson chart (Clement Clarke Inc., Harlow, UK) at a 
distance of 1m and chart luminance of 80–120cd/m2, RG and YB chromatic 
sensitivity (measured monocularly in each eye using the CAD test), reading 
acuity and speed were measured using a standardized protocol with the 
MNREAD acuity charts (Precision vision, IL, USA), and microperimetry using the 
Nidek Microperimeter (Nidek Technologies, Padova, Italy). Macular stereo, four 
field fundus colour photographs and fundus fluorescein angiography were also 
performed at baseline and week 24.  
 
All patients were refracted by a certified examiner and BCVA for each eye was 
measured using standard ETDRS protocol at 4m distance with a modified ETDRS 
distance chart. Visual acuity was scored as the total number of ETDRS letters 
read correctly. My role included taking medical and ophthalmic history, 
examining subjects using a slit lamp for biomicroscope, dilated fundoscopy and 
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IOP measurement, consenting and monocular measurements of chromatic 
sensitivity, using the CAD test. 
 
All patients had the Ozurdex (Dexamethasone implant) intravitreal injection on 
week 1. According to the protocol some of the patients were eligible for a 
second injection at the re-treatment window between week 16 and week 24. 
 
The patient’s CV thresholds are compared to the corresponding visual acuity, 
the measured change in retinal central sub-field thickness (CST) and are 
presented in this thesis. Other visual parameters measured such as contrast 
sensitivity, reading speed and central fixation which relate to the OCTOME study 
have been published under the title OCTOME report 1 (Mathew et al., 2014). 
 
5.2.3 STATISTICAL ANALYSIS 
 
The data were analysed using MS Excel (V.15.0) and SPSS programs (SPSS V.22.0, 
SPSS, Chicago, IL, USA). Analysis was performed using t-tests to calculate p 
values and categorical variables were examined using Pearson’s r correlation. 
Differences in results were assumed significant for p-values <0.05.  
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5.3 Results 
5.3.1 Descriptive data 
The study included 14 patients. The patients demographic and baseline 
characteristics are shown in table 5-1. 
Mean age (SD), years                                                                   56±9.23 
Range, years                                                                                  40-68 
Gender, n (%) 
    Male, n (%)        12 (85.7) 
 Female, n (%)                                                    2 (14.2) 
Race, n (%) 
    Afro-Caribbean                                                                   4 (28.6) 
    Asian           2 (14.3) 
 Caucasian                                                                              8 (57.1) 
Grade of diabetic retinopathy, n (%) 
 Mild and moderate NPDR      6 (42.8) 
 Severe NPDR        3 (21.4) 
 Treated PDR        5 (35.7) 
Smokers, n (%)         2 (14.3) 
Mean HbA1C, n* (SD)       7.8±1.39 
 ≤8%, n (%)         6 (50) 
 >8%, n (%)         6 (50) 
Hypertensives on treatment, n (%)      9 (64.3) 
Previous glaucoma medications      0 
Previous macular laser, n (%)       12 (85.7) 
Mean number of laser treatments, n (SD)     2.2±1.6 
Mean ETDRS letter score, n (SD)      59.71±9.20 
 <54 letters (0.92 LogMAR), n (%)     4 (28.6) 
 ≥54 letters (0.92 LogMAR), n (%)    10 (71.4) 
 
 
Abbreviations: ETDRS, early treatment diabetic retinopathy study; HbA1C, glycosylated 
haemoglobin; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic 
retinopathy. 
*n =12, as data is missing for 2 patients 
Table 5-1: Patients demographic and baseline characteristics. 
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5.3.2 Lens opacity 
It has been reported that the age related changes occurring in the human optical 
system can induce a tritan-like CV defect (Verriest, 1963). The lens yellowing and 
senile pupil miosis have been attributed to the age related deterioration of CV 
with a reduction in retinal illuminance (Winn et al., 1994; Verriest, 1963). The 
density of cataract in the current study was graded using Lens Opacities 
Classification System III (LOCS III) (Chylack et al., 1993). 12 (85%) of patients were 
phakic with nine of them graded as N1C1P1, the other 3 were graded as N1C2P1 
and the remaining 2 patients were pseudophakic (subjects 6 and 12). 
 
5.3.3 Change in RG and YB thresholds 
 
The mean age in our patients was 56 years (range, 40 to 68) and the age specific, 
monocular, upper normal limits for a 56 years old subject (i.e., ) are 2.66 
and 2.85 CAD SNU for RG and YB, respectively. In this study, all the patients were 
outside the normal age-matched upper threshold limits with the mean RG pre-
injection threshold of 22.57 ±11.27 SNU (range, 2.95 to 35.87) while the YB 
mean threshold was 16.21 ± 3.76 SNU (range, 15.18 to 18.19). 
There was significant improvement in RG thresholds post injection (i.e., ) 
19.18 ±10.84 SNU (t (13) =1.965, p<0.05). The post injection YB threshold, 
although smaller, failed to reach statistical significance (±2 15.84 ± 4.60 SNU 
(t (13) = 0.747, p=0.23). Only four patients showed improvement in their YB 
threshold (Table 5-2). 
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The percentage changes in RG and YB thresholds after receiving Ozurdex 
intravitreal injection are shown in figure 5-1. 
 
 
Figure 5-1: Graphs showing the effect of Ozurdex on measured changes in 
Red/Green (RG) and Yellow/Blue thresholds (YB). 8 subjects showed 
significant improvement in RG thresholds post injection (between 10-70% 
improvement). YB thresholds showed less significant improvement, with only 
4 subjects showing post injection improvement. All the subjects that showed 
improvement in RG, also showed improvement YB thresholds. 
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5.3.4 Change in visual acuity 
The number of patients who gained more than 5 or 15 letters by week 24 were 
6 (42.8%) and 4 (28.5%) respectively. Three patients (21.42%) lost 2 letters or 
less, with another patient losing 9 letters by week 24 (Table 5-2). 
There was a strong correlation between the percentage improvement of RG 
threshold and visual acuity (r (14) = 0.69; p<0.05), while the YB did not show 
correlation with visual acuity (r= (14) = 0.04; p<0.05). 
The percentage change in VA after receiving Ozurdex intravitreal injection are 
shown in figure 5-2. 
 
 
Figure 5-2: Graph showing the effect of Ozurdex on measured changes in visual 
acuity (VA). 10 subjects (71%) showed 5 or more letters improvement in visual 
acuity post injection. 4 subjects (29%) experienced worsening of vision by 2-9 
letters. 
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5.3.5 Change in central sub-field thickness (CST) 
The  ±2 CST pre-treatment with Ozurdex was 542 ±135 µm (range, 315 to 881 
µm). After treatment and by week 24 the mean±CST has been reduced to 435 
±127 µm (range, 235 to 692 µm) (t (13) = 2.202, p<0.05). 
There was strong correlation between the percentage improvement of RG and 
CST (r (14) = 0.78; P<0.05), while the YB threshold changes failed to show 
significant correlation with CST (r= (14) = -0.31). 
The percentage change in CST after receiving Ozurdex intravitreal injection are 
shown in figure 5-3. 
 
 
 
Figure 5-3: Graph showing the effect of Ozurdex on measured changes in 
central sub-field thickness (CST). 6 subjects showed 25% or more reduction in 
CST. 3 subjects showed less than 25% reduction in CST while there was 
increase in CST in 5 patients. 
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The mean decrease in CST showed an initial significant improvement that was 
more evident by week 8, then started to show minimal change from week 16 
(Figure 5-4). 
 
 
Figure 5-4: Graph showing the change in central sub-field thickness (CST) from 
baseline over the period of 24 weeks. Significant improvement was more 
evident by week 8, then started to show minimal change from week 16 
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5.3.6 Change in visual functions 
Other visual functions measured at baseline and at week 24 included contrast 
sensitivity, reading speed and central retinal sensitivity at 4°. At baseline the 
contrast sensitivity was 31.15 ± 3.05, while reading speed was 164.14   
±50.49 wpm and central retinal sensitivity was 5.63 ± 5.03.  
On measuring these parameters again at week 24 it was noticed that there was 
improvement in all of them, more noticeable though in the retinal sensitivity 
and reading speed (Table 5-3). 
We examined the correlation between the RG and YB thresholds and other 
visual functions before and after injection as it was of interest to note the high 
correlation between the contrast sensitivity and the RG thresholds, before: (r= 
(14) = 0.60; p<0.05) and after: (r= (14) = 0.68; p<0.05), respectively. The same 
high correlation was also present between the RG thresholds and retinal 
sensitivity, before: (r= (14) = 0.77; p<0.05) and after: (r= (14) = 0.73; p<0.05) 
treatment. 
As for the YB thresholds, there was a high correlation with contrast sensitivity 
before but not after injection, (r= (14) = 0.64; p<0.05) (r= (14) = 0.38; p<0.05), 
respectively. The same was seen with retinal sensitivity with high correlation 
before but not after injection, (r= (14) = 0.83; p<0.05) and (r= (14) = 0.17; 
p<0.05), respectively. 
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Visual function Baseline Week 24 Mean change ± SD 
Contrast sensitivity 31.15 ± 3.05 33.14 ± 2.44 1.99 ± 0.61 
Retinal sensitivity 4° 5.63 ± 5.03 10.46 ± 5.86 4.83 ± 0.83 
MNREAD reading speed 164.14 ± 50.49 194.14 ± 66.89 30 ± 16.4 
Central fixation, n (%) 7 (50) 7 (50)  
Table 5-3: Visual functions at baseline and week 24. 
 
 
 
 
                                      Week 1 (Before treatment)                Week 24 (After treatment) 
 
 
 
 
 
 
RG (SNU) 11.14 RG (SNU) 8.84
YB (SNU) 11.71 YB (SNU) 5.98
Subject A
Week 1 (Pre-treatment) Week 24 (Post-treatment)
0.14 0.26 0.38 0.5
x
0.16
0.28
0.4
0.52
y
0.14 0.26 0.38 0.5
x
0.16
0.28
0.4
0.52
y
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                                      Week 1 (Before treatment)                  Week 24 (After treatment) 
 
Figure 5-5: The graphs show CAD results before and after Ozurdex treatment 
in two subjects with diabetes (A=11, B=4). Both subjects show significant 
improvement in colour sensitivity (i.e., smaller thresholds) post treatment. 
The grey, dotted lines show the colour limits imposed by the phosphors of the 
display. Subject B was unable to detect YB colour changes, even for the largest 
chromatic stimuli that are limited only by the phosphors of the display. Post 
treatment the YB thresholds remain at these limits with only a small indication 
of improvement. The RG thresholds, on the other hand, show significant 
improvement post-treatment. 
  
RG (SNU) 25.64 RG (SNU) 17.19
YB (SNU) 18.17 YB (SNU) 17.71
Subject B
Week 1 (Pre-treatment) Week 24 (Post-treatment)
0.14 0.26 0.38 0.5
x
0.16
0.28
0.4
0.52
y
0.14 0.26 0.38 0.5
x
0.16
0.28
0.4
0.52
y
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6 DISCUSSION 
The main purpose of this study was to investigate changes in CV in patients with 
diabetes. In addition, we wanted to ascertain whether it was possible to detect 
early functional changes in the diabetic retina before structural changes could 
be detected on clinical examination or fundus imaging. We also wanted to grade 
the severity of CV loss in comparison to other factors that are normally linked to 
diabetes, such as the type, grade, control and duration. We also measured 
changes in CV in a group of diabetic patients with DMO undergoing intravitreal 
injection of dexamethasone implant (Ozurdex). 
The study used the CAD test which has the advantage of being highly sensitive 
with the ability to quantify the severity of RG and YB loss. The availability of 
statistical, upper limits for normal CV as a function of age makes the CAD test 
particularly suitable in detecting and quantifying acquired loss of CV in retinal 
disease. 
To maximise the loss of CV that can be attributed to diabetes, a carefully 
designed selection process was applied. Those with congenital CV deficiencies, 
subjects who exhibit RG losses whilst maintaining normal YB thresholds, were 
not included in the analysis and subjects with any co-pathology that might 
impair CV were also excluded. Subjects on medications that are known to affect 
CV were also excluded. So none of the subjects included in this study were taking 
Digoxin ethambutol, chloroquine, hydroxychloroquine, phenytoin or sildenafil. 
The results show that subjects with no DR will exhibit a degree of CV loss which 
confirms findings suggested in previous study by Feitosa-Santana et al., (2006), 
who reported on 32 diabetic subjects with no DR. Subjects were tested using the 
Farnsworth D-15 and the Lanthony D-15d arrangements tests. Results were 
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compared to 20 age matched normal controls. Their subjects showed 
compressed colour space configuration along the YB and RG axes in diabetic 
subjects with no retinopathy. They proposed that these losses resulted from 
reduced photoreceptor sensitivity rather than being a manifestation of lens 
yellowing. 
To our knowledge, the CAD test has only previously been used to measure 
binocular thresholds in diabetes without retinopathy (Barbur et al., 2012) and in 
another small study which was conducted by O’Neil-Biba et al., (2010) that also 
involved binocular measurements; they measured CV in 7 diabetic patients, 2 
with type I and 5 with type II diabetes. Their results demonstrated reduced 
chromatic sensitivity with varying degrees along the RG and YB spectrum in 
patients with no or mild DR and no correlation with duration of the disease. 
This confirms the influence of the neuronal retinal changes that precedes 
microvascular changes as reported by Antonetti et al., (2006). These sub clinical 
changes cannot be detected by conventional methods currently used in diabetic 
screening such as fundus photography or OCT.  
We also found that the severity of CV loss correlates with the severity of DR 
although this wasn’t significant but this is in agreement with a previous study by 
Roy et. al., (1984), that found correlation between the FM-100 error score and 
degree of retinopathy. Also in 1998, Ismail and Whitaker reported that the level 
of mean error score increased with the severity of DR. 
The losses in CV thresholds could not be attributed to other diabetes related 
factors such as duration, type or control. This was similar to findings from 
previous studies, in 1986, Roy et. al., reported no correlation between the FM-
100 error score and fasting blood sugar. A separate study by Kurtenbach et al., 
(1999), which analysed blood glucose levels in 10 diabetic patients with no signs 
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of retinopathy, found no correlation between blood glucose levels and the 
measured CV deficits. Another study by Ong et. al., (2003) failed to show a 
correlation between CV and duration of diabetes. While other studies did report 
correlation with duration of disease such as Kurtenbach et al., (1999) and Utkah 
and Almaca (1992) who reported correlation between the duration and error 
scores measured in 87 diabetic patients using FM-100 hue test. 
Although several studies have found reductions in CV that do not appear to 
relate to the type, duration or control of diabetes. Unfortunately none of these 
studies provide a definite explanation as to the exact aetiology or mechanism by 
which colour vision is affected. The exact processes involved are not 
understood, but theories have been advanced to account for the observed 
changes in colour vision. The most common theories include inflammation, 
apoptosis and glutamate excitotoxicity (discussed in detail in section 2.3.1).  
In 2015, Barbur et al. reported on the normal limits for age. These limits were 
calculated from data obtained from measuring RG and YB thresholds in normal 
subjects using the CAD test. Similar to our inclusion criteria, any subjects with 
nuclear, cortical or subcapsular lens opacities higher than grade 2 were excluded 
from the study. They also excluded any subject with congenital colour 
deficiency, subjects with medical conditions such as diabetes and hypertension 
and, or any other subjects that might have any other ocular abnormalities that 
might cause acquired loss of chromatic sensitivity.  
Using this large data set it was possible to calculate the mean thresholds and the 
corresponding ±2.5σ limits as a function of age. The results showed that above 
20 years of age the mean linear increase in RG and YB thresholds is 1% and 1.6% 
per year respectively. 
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It was important to establish that the colour threshold changes measured in the 
subjects investigated in this study reflect the effects of diabetes and not the 
effects of normal aging of the eye. The results were therefore compared to the 
upper, normal thresholds for age matched subjects. 
In 20 of our subjects, either the RG or YB thresholds (18 for RG and 4 for YB) 
were within normal limits for the corresponding age. Only two of these subjects 
had both the RG and YB thresholds within normal limits.  As described in the 
results chapter, the results were analysed both with and without including those 
subjects but this made no difference to the final outcome.   
Chromatic sensitivity has been found to decline with increasing age. This has 
been attributed to the loss of retinal ganglion cell axons and cell bodies in the 
neuronal retina (Jonas et al, 1990). Changes to the visual system also take place 
involving the loss of myelinated axons and alterations to the spatial distribution 
of myelin in the nerve fibres in the deeper layers of the visual cortex affecting 
visual processing (Peters at al. 2000, 2001). Colour sensitivity does not appear 
to be affected by other age related factors such as moderate increases in 
crystalline lens opacification, changes to the macular pigments and a reduction 
in the size of the pupil (Werner et al., 2004; Rodriguez-Carmona et al., 2006; 
Barbur, 2012), provided adequate lighting levels are used during the 
assessment. In general, these factors cause increased preferential absorption of 
short wavelength light and this can affect chromatic sensitivity when the 
ambient light level is low. The effect is not however specific to short wavelength 
light and can also be demonstrated by using a neutral density filter that causes 
an overall reduction in retinal illuminance. This may account for the more rapid 
loss of YB chromatic sensitivity. Stimulus size is also an important variable 
causing significant loss of both RG and YB chromatic sensitivity (Barbur & 
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Rodriguez-Carmona, 2012). The CAD test employs photopic levels of retinal 
illuminance and a large stimulus size to ensure that small changes in retinal 
illuminance or stimulus size do not affect the measured colour thresholds.   
In the other group of diabetic patients with DMO we examined the changes in 
CV in eyes undergoing intravitreal injection of dexamethasone implant 
(Ozurdex). All patients showed loss of RG and YB thresholds at recruitment to 
the study but they responded differently post injection with the majority 
showing greater improvement in RG sensitivity. This improvement correlated 
well with the increase in visual acuity. In the related study-OCTOME, the 
maximum gain in visual acuity was achieved 12 weeks post Ozurdex injection. At 
20 weeks post treatment, while the gain in visual acuity started to regress, CV 
maintained the thresholds that were achieved post injection especially along the 
RG axis. 
 
The mean decrease in CST showed a similar trend with initial significant 
improvement that was more evident by week 8, then started to show minimal 
change from week 16 (Figure 5-4). 
 
 
Again the mechanisms by which CV is affected in DMO remain poorly 
understood. Some explanations have been put forward to account for the 
observed losses, but these have not been satisfactory. Several studies (Barber 
et al., 1998 & 2011; Nishikawa et al., 2000; Hammes et al., 2003) examined the 
events of vascular and neuronal apoptosis that occur in DR as the prime cause 
of CV loss. These studies above focused on the various mechanisms that are 
thought to cause retinal cell apoptosis (vascular and neuronal retina). Exposure 
to oxidative stress and reduced growth factor signalling have been identified as 
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potential factors that may play a key role. Oxidative stress can be induced by 
hyperglycaemia leading to apoptotic signalling. Growth factor signalling is 
essential for the survival of neurones, pericytes and endothelial cells. They 
explained that diabetes impairs the trophic signals pathway leading to reduction 
in survival signals and hence increasing the chances of apoptosis.  
 
Barber at al., (2003) also demonstrated that glutamate excitotoxicity can cause 
damage to the neuronal retina and therefore contribute to both chronic and 
acute neurodegeneration. Neuro-inflammation is also an important factor to be 
considered in the pathology of DR and subsequent CV defects. Some studies 
(Seigel et al., 2000; Barber at al., 2001; Gariano et al., 2005) have identified 
increased levels of cytokines, specially vascular endothelial growth factor 
(VEGF), interleukin (IL)-1 B, IL-6, IL-8 and tumour necrosis factor (TNF)-α in the 
vitreous of DMO patients and patients with PDR. 
 
The effect of circulating oxygen saturation on colour thresholds has also been 
investigated (Dean et al., 1997). The authors examined 37 Type I diabetics with 
either mild or absent DR. An improvement in colour thresholds was 
demonstrated in all subjects after breathing oxygen (100%). They concluded 
that reduced oxygen saturation can lead to impaired CV which is likely to be 
because photoreceptors are functioning at suboptimal oxygen levels. A similar 
study conducted by Connolly et al., (2008) showed that chromatic sensitivity was 
impaired in aircrew when subjected to mild hypoxia as opposed to those under 
normoxic or hyperoxic conditions. 
 
A majority of our patients showed significant improvement in the morphology 
of the macula on OCT scan at one month following their injection. This initial 
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improvement in visual acuity and CST regressed slightly in the following weeks 
while the initial improvement in chromatic sensitivity was maintained for a 
longer period, until week 24. 
The almost immediate fluid drying effect of the Ozurdex on the macula with 
restoration of anatomical structure can be seen in OCT images. This does not, 
however, reflect the extent of damage sustained in the neural retina and can 
affect some aspects of visual performance. In order to assess the full extent of 
damage caused by diabetes, the measurement of other visual attributes 
becomes of interest. Assessment of chromatic sensitivity changes as shown in 
this study can have an important role in assessing the progress of diabetes and 
the effectiveness of treatment. 
 
DMO is the major contributing factor to loss of sight in DR. It is therefore 
important to detect and monitor changes in foveal vision during the course of 
diabetes.  In addition, it is equally important to be able to detect and monitor 
how visual performance changes during the course of treatment so as to be able 
to assess objectively the effectiveness of treatment.    
 
All patients who underwent treatment with dexamethasone implant (Ozurdex) 
had chronic DMO, therefore they would have had previous treatments such as 
laser - focal or grid, intravitreal triamcinolone and anti-VEGF injections. Given 
the advanced level of damage to the retina, it was not unexpected to find 
significant loss of CV in all patients with the YB thresholds being most affected. 
All of our patients except for two had a degree of cortical and posterior 
subcapsular cataract which is a known association with diabetes (Olafsdottir el 
al., 2011). These observations may explain the improvement of RG thresholds, 
but not in YB thresholds post treatment with Ozurdex.  
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The findings suggest that RG threshold as quantified with the CAD test can be 
used to monitor treatment of DMO. At base line all our patients showed higher 
loss of RG than YB thresholds, but post injection with Ozurdex nine out of 14 
patients showed significant improvement in RG thresholds while YB did not 
show that level of improvement. 
 
The current findings are consistent with the outcome of the OCTOME study in 
relation to the overall improvement in visual functions post Ozurdex injection. 
The findings from the OCTOME study “indicate a positive effect on the retinal 
neuronal function, probably due to a realignment of neuronal structures 
induced by the drying effect of Ozurdex” (Mathew et al., 2014). The significant 
improvement in RG chromatic sensitivity observed in this study supports this 
claim and is consistent with the view that ‘A direct neurotrophic effect of 
Ozurdex cannot be ruled out‘.  
 
To our knowledge this is the first study to examine the effect of Ozurdex 
intravitreal injection on CV. It may be of great benefit in the future to conduct a 
similar study to investigate changes in CV, contrast sensitivity and rapid flicker 
in naïve patients with DMO who are receiving Ozurdex as their first line of 
treatment. Such a study may reveal the full functional benefits of Ozurdex 
treatment and not just the improvement in BCVA and macular morphology.   
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CONCLUSIONS  
The findings from our study reveal positive correlation between the chromatic 
sensitivity loss and the severity of DR. It also shows that CV loss occurs in 
diabetics before any vascular changes are detected by the conventional means 
currently used in assessing DR such as fundus imaging and clinical examination. 
These findings suggest that using the CAD test can provide a sensitive means of 
measuring colour thresholds to reflect the health of the retina and detect any 
functional changes that precede structural changes which is important in 
monitoring the progression of DR. 
Also our study of DMO patients reveal significant improvement in RG colour 
thresholds as a result of treatment with Ozurdex, with little or no improvement 
in YB thresholds. The improvement in chromatic sensitivity correlates well with 
the associated improvement in visual acuity and CST.  In addition to VA and OCT 
measurements, the findings from this study suggest that changes in CV and 
particularly in the RG chromatic mechanisms can provide a useful biomarker in 
monitoring the efficacy of treatment in DMO. 
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LIMITATIONS AND FUTURE WORK 
The main limitation to our study was the difference in distribution of numbers 
of subjects included in each of the group. We had less number of subjects 
recruited in group 2 (moderate or severe) and group 3 (treated PDR) and this is 
attributed to the efficacy of current screening programmes as we are seeing less 
and less numbers of patients with advanced DR in the clinics. 
 
It would be of great interest to follow-up on the patients who had no signs of 
DR but still exhibited a degree of CV loss to establish whether they develop 
clinical signs later. Also the other groups of patients to detect if a change in the 
grade of DR will correlate with change in their CAD test thresholds. A 
longitudinal study in the future would be very useful to establish this. 
 
The findings from the study of patients treated with Ozurdex for DMO would 
have been more convincing with a larger sample size. Unfortunately not all of 
the diabetic subjects recruited in the OCTOME study were able to perform the 
CAD test, either due to limited cognitive ability or because of severe loss of vision 
which hindered their ability to complete successfully the one minute learning 
stage of the test. The CAD test does offer the option of increasing the stimulus 
size which may have allowed some of these patients to carry out the test. This 
may have, however, been of limited value as we would not have been able to 
correlate it with the remaining parameters that would have already been 
affected by the extensive loss of vision. It would be useful to design a study to 
include treatment naive DMO patients rather than chronic DMO patients. The 
patients that we were able to examine exhibited greater loss of YB sensitivity 
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compared to RG which may have contributed to the fact that lens opacity can 
reduce retinal illuminance levels and that this in turn can cause a significant 
reduction in YB sensitivity. This may explain why post injection there was much 
greater improvement in measured RG thresholds as compared to YB thresholds. 
As per the protocol of the OCTOME study the CAD test was only done once after 
the injection, at week 24, but it may be useful in future studies to examine the 
patients again beyond week 24 to find out if the observed improvement in RG 
colour thresholds is sustained.  
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